


# Red Alert for Women's Hearts

Women and Cardiovascular Research in Europe

November 2009



EUROPEAN  
SOCIETY OF  
CARDIOLOGY<sup>®</sup>

# Red Alert on Women's Hearts

## Women and Cardiovascular Research in Europe

November 2009

European Heart Health Strategy  
EuroHeart Project, Work Package 6  
Women and Cardiovascular Diseases

**Marco Stramba-Badiale, MD, PhD**

*Department of Rehabilitation Medicine  
IRCCS Istituto Auxologico Italiano, Milan, Italy*

Marco Stramba-Badiale, MD, PhD  
Department of Rehabilitation Medicine  
IRCCS Istituto Auxologico Italiano  
Via Mosè Bianchi, 90  
20149 Milan, Italy  
Tel & fax +39.02.619112850  
stramba\_badiale@auxologico.it





# Table of Contents

---

<b>Members of the Advisory Board</b> .....	<b>3</b>
<b>Summary</b> .....	<b>4</b>
<b>Introduction</b> .....	<b>5</b>
<b>Background</b> .....	<b>6</b>
Gender, epidemiology of cardiovascular diseases, and inequalities in life expectancy among European countries .....	6
Cardiovascular diseases in women: the need for action .....	7
Under-representation of women in clinical trials.....	7
Women and research on cardiovascular diseases: the European Heart Health Strategy (EuroHeart) project.....	8
<b>Outcome of the research</b> .....	<b>10</b>
Age, menopause and the cardiovascular risk in women .....	10
Cardiovascular risk assessment and management in women .....	12
Gender and blood pressure-lowering treatment.....	14
Diabetes and the metabolic syndrome in men and women.....	16
Cholesterol-lowering therapy and cardiovascular prevention in men and women .....	17
Aspirin for secondary and primary prevention: Do gender differences exist?.....	19
Gender differences in ischemic heart disease.....	20
Acute coronary syndromes and coronary revascularization from a gender perspective.....	22
Gender differences in heart failure.....	23
Gender and atrial fibrillation .....	25
Gender differences in stroke.....	26
<b>Conclusions</b> .....	<b>28</b>
<b>Table and Figures</b> .....	<b>31</b>
<b>References</b> .....	<b>35</b>

# Members of the Advisory Board

---

Members of the Advisory Board of Work Package 6 of the EuroHeart project are:

- u Harisios Boudoulas (Hellenic Cardiac Society, Greece)
- u Emanuela Folco (Italian Heart Foundation, Italy)
- u Marleen Kestens (European Heart Network)
- u Susanne Løgstrup (European Heart Network)
- u Peggy Maguire (European Institute of Women's Health, Ireland)
- u Ruairi O'Connor (British Heart Foundation; United Kingdom)
- u Sophie O'Kelly (European Society of Cardiology)
- u Karin Schenck-Gustafsson (Karolinska University Hospital, Sweden)
- u Hans Stam (Netherlands Heart Foundation, Netherlands)
- u Marco Stramba-Badiale (IRCCS Istituto Auxologico Italiano, Italy)
- u Saila Vikman (Finnish Cardiac Society, Finland).





## Summary

Cardiovascular diseases represent the major cause of mortality in women and in men. The results of large randomized clinical trials allowed the introduction of preventive measures and effective treatments with a significant improvement of survival and reduction of disability. However, sex and gender differences in the clinical presentation of cardiovascular diseases have been demonstrated and some therapeutic options may not be equally effective and safe in men and women. Under-representation of women in cardiovascular research has been clearly demonstrated in the past and, recently, efforts to enrol a larger number of women in clinical trials have been made.

One of the objectives of Work Package 6 of the EuroHeart project, conducted jointly by the European Heart Network and the European Society of Cardiology, was to assess the representation of women in cardiovascular research in Europe. A search was conducted in order to identify publications (European or international with European representation) of randomized clinical trials which enrolled women and men or women only.

The 62 randomized clinical trials published since 2006 and analyzed here, enrolled overall 380,891 participants and 127,716 were women (33.5%) (See table 1 on page 31 for a summary). Mean age of participants was 66.3 years and mean follow-up 2.7 years. The percentage of women enrolled in each trial ranges from 15% to 60%, but only 31/62 trials (50%) reported the analysis of the results by gender. The representation of women in the clinical trials is not homogeneous. Trials performed on blood pressure lowering therapies, diabetes, atrial fibrillation and stroke enrolled approximately 40% of women, while trials performed on cholesterol-lowering therapy and on management and treatment of ischemic heart disease and heart failure enrolled about 30% of females. Most of the clinical trials and meta-analyses on cardiovascular diseases did not report a significantly lower efficacy of interventions in the outcomes in women when compared with men. For some therapies there is even a suggestion for greater efficacy in women than in men, as in

the case of cardiac resynchronization therapy in heart failure or thrombolysis after ischemic stroke. Women may have more frequently adverse effects, such as for newer glucose-lowering agents, or in the treatment of acute coronary syndromes, where they appear to be more prone to bleedings. Some trials provided conflicting results in women, for example in the assessment of the efficacy of early invasive strategies in acute coronary syndromes.

**Despite an increase in the number and proportion of women enrolled in cardiovascular clinical trials, there is still an under-representation of women, particularly in the field of cholesterol-lowering therapy, ischemic heart disease and heart failure, which may have affected the reliability of subgroup analysis.**

Although gender issues are addressed, Scientific Guidelines do not generally provide specific recommendations for prevention or treatment in women. Thus, despite an increase in the number and proportion of women enrolled in cardiovascular clinical trials, there is still an under-representation of women, particularly in the field of cholesterol-lowering therapy, ischemic heart disease and heart failure, which may have affected the reliability of subgroup analysis. Furthermore, approximately 50% of the trials did not report an analysis of the results by gender. Clinical trials enrolling only female patients or clinical trials enrolling a significant proportion of women to allow for prespecified gender analysis should be conducted. Initiatives which contribute to increase the awareness in Europe that cardiovascular diseases are the major cause of death in women and to improve the knowledge of risk factors, presentation and treatment of cardiovascular diseases in women should be encouraged. Scientific societies, patients' associations and foundations should cooperate with European institutions, national health care authorities and regulatory agencies to promote scientific research on gender issues in cardiovascular medicine and a larger representation of women in clinical trials.

# Introduction

---

Despite a significant decline in the incidence of cardiovascular diseases in the last 50 years, ischemic heart disease and stroke still represent the major cause of mortality, morbidity and disability in women as well as in men (1). The identification of risk factors for cardiovascular diseases in large epidemiological studies allowed the performance of randomized clinical trials to test the efficacy and safety of preventive interventions. Furthermore, significant improvement of survival and reduction of disability has been made possible by clinical research on interventions in the acute phase of cardiovascular events and on the efficacy of long-term therapies for secondary prevention.

However, gender differences in the clinical presentation of cardiovascular diseases have been demonstrated (2) and some therapeutic options may not be equally effective and safe in men and women (3). Accordingly, it is crucial that preventive and therapeutic interventions are tested in populations that fairly represent the gender distribution for each specific clinical condition or group at risk. Underrepresentation of women in cardiovascular research has been clearly demonstrated in the past. More recently, special attention has been paid to the issue of cardiovascular diseases in women and there is a growing interest for gender-specific cardiovascular medicine. Scientific societies, patients associations and heart foundations undertook several initiatives to increase the awareness of cardiovascular diseases

in women and the representation of female gender in clinical research. Regulatory agencies in the USA but also in Europe have tried to encourage the inclusion of a higher proportion of women in clinical trials and some studies have been performed in populations of women only (4).

The European Heart Health Strategy (EuroHeart) project is a joint initiative of the European Society of Cardiology (ESC) and the European Heart Network (EHN), co-funded by the European Commission and launched in April 2007. One of the objectives of this project is to improve the awareness, diagnosis and treatment of cardiovascular diseases in women across Europe. One specific aim was to analyze campaigns targeting women to increase their awareness of cardiovascular diseases as well as educational programmes for health professionals. Another objective was to address the issue of women representation in cardiovascular clinical research by collecting information on clinical trials and registries in Europe. Furthermore, possible gender differences in the primary outcomes of these trials and in the current clinical practice together with the presence of gender issues in Scientific Guidelines of European scientific societies have been assessed. This document summarizes the results of the analysis by critically reviewing the most significant findings. The analysis of the awareness campaigns and educational programmes is described elsewhere.



# Background

## Gender, epidemiology of cardiovascular diseases, and inequalities in life expectancy among European countries

Cardiovascular diseases are the leading cause of death in men and women, as indicated by data released in 2008 by the World Health Organization, accounting for 43% of deaths in men and 54% in women in Europe (1). Specifically, coronary heart disease represents 21% of deaths in men and 22% in women, whereas stroke is a more frequent cause of death in women than in men (17% and 11%, respectively), as well as the other cardiovascular diseases (15% in women and 11% in men). Thus, stroke represents the third cause of death in men and the second in women.

**In younger age groups the prevalence of cardiovascular diseases is lower in women when compared to men, and the reverse is true at older ages. The prevalence of stroke is slightly higher in men than in women, irrespective of age.**

The prevalence and incidence of cardiovascular diseases among both men and women increase with age (2). However, in younger age groups the prevalence of cardiovascular diseases is lower in women when compared to men, and the reverse is true at older ages. The prevalence of stroke is slightly higher in men than in women, irrespective of age.

There has been an age-adjusted decline in mortality for cardiovascular diseases in the last 50 years in Western countries, but this decline was less pronounced in women.

Although life expectancy is increasing in Europe, significant inequalities have been demonstrated across the European countries (1). In Eastern Europe life expectancy is lower than in Western Europe with relevant gender differences. More specifically, in 2005 men of Eastern Europe showed an excess mortality of 13.3 years compared to men in Western Europe, mostly in the group below the age of 60, while the

7.9 years of excess mortality in women occurred at older ages. In fact, of the whole difference in life expectancy in men, approximately 65% was due to excess mortality in the 15–59-year age group, while in women the difference in life expectancy was largely the result of higher mortality in those over the age of 60 (contributing to 50%). The single most important contributor to excess mortality in Eastern Europe is cardiovascular disease. However, while among males less than 50% of the excess mortality was due to cardiovascular diseases, in females the contribution of cardiovascular diseases was approximately 80%

**The single most important contributor to excess mortality in Eastern Europe is cardiovascular disease. However, while among males less than 50% of the excess mortality was due to cardiovascular diseases, in females the contribution of cardiovascular diseases was approximately 80%.**

Life expectancy might not fully reflect the actual health condition of the population. When life expectancy without activity limitation is considered, similar inequalities between European countries have been found (5). Healthy life years at age 50 by sex and country have been calculated for 25 countries in the European Union (before the enlargements to the last 2 new members). In 2005, an average 50-year-old man could expect to live until 67.3 years free of activity limitation, and a woman until 68.1 years. Of note, healthy life years at age 50 for both men and women varied between countries (from 9.1 years in Estonia to 23.6 years in Denmark for men; from 10.4 years in Estonia to 24.1 years in Denmark for women). Thus, citizens of the 15 European countries which formed the EU before the recent enlargements have both longer and healthier lives than do most of those of the 10 new European Union countries. These findings suggest

that, without major improvements in population health, life expectancy without activity limitation will remain lower in a significant proportion of the 25 European Union countries.

**Without major improvements in population health, life expectancy without activity limitation will remain lower in a significant proportion of the European Union countries.**

## **Cardiovascular diseases in women: the need for action**

In the last 20 years, several initiatives have been undertaken in order to increase the awareness and the management of cardiovascular diseases in women in different countries. One example is the “Go Red for Women” campaign conducted in the USA with the goal of reducing the impact of cardiovascular risk factors among women and increasing the knowledge of cardiovascular diseases among health professionals but also in the general population.

In 2005 the European Society of Cardiology launched the “Women at Heart” programme in order to organize initiatives targeted at promoting research and education in the field of cardiovascular diseases in women. Among these initiatives an analysis of the European Society of Cardiology Euro Heart Survey - a programme aimed at monitoring clinical practice in Europe - has been performed in order to assess

possible differences between women and men in the management and treatment of cardiovascular diseases.

The European Society of Cardiology promoted also a Policy Conference, held in Nice in June 2005, with the objective of summarizing the state of the art in Europe, identifying the scientific gaps in research on cardiovascular diseases in women and delineating the strategies for changing the misperception of cardiovascular diseases in women, improving risk stratification, diagnosis and therapy from a gender perspective and increasing women representation in clinical trials. The Statement from the Policy Conference which summarized the main topics of the discussion and provided recommendations to diminish the impact of cardiovascular diseases in women has been published in the European Heart Journal and translated in different languages (2).

## **Under-representation of women in clinical trials**

It has been suggested that gender differences in the response to cardiovascular therapy may be identified (3) and that understanding these differences may improve the clinical management of cardiovascular diseases and, in the future, develop possible gender-specific diagnostic and therapeutic strategies. However, women have been under-represented in randomized clinical trials and only recently the percentage of women enrolled has increased. As a consequence, safety and efficacy of several drugs have been evaluated predominantly in male populations.

In a study funded by the NHLBI which investigated the enrolment of women in mixed-gender cardiovascular clinical trials between 1965 and 1998, the overall proportion of women enrolled was 38% (6). An updated analysis of the enrolment of women in mixed-gender NHLBI-sponsored randomized controlled trials with primary outcomes of stroke, myocardial infarction, or death published between 1997 and 2006 showed that the proportion of women was 27% and only 13 of 19 studies included in this analysis reported gender-based outcomes in their primary report (7).



In the cardiovascular clinical trials performed almost exclusively in European countries in the same period, the proportion of women enrolled varied between 16 and 25%, although the female prevalence of the clinical condition under study in the general population was similar to that of men.

In 2005, the European Medicines Agency (EMA) released a document on gender considerations in the conduct of clinical trials, emphasizing the importance of a fair representation of women. Furthermore, the Policy Conference on Cardiovascular Diseases in Women (2) noted that there was a lack of conclusive data on the magnitude of gender differences in the response to cardiovascular therapies and an important recommendation was to stimulate basic and clinical research to advance the knowledge on this topic. Although non prespecified, post-hoc, subgroup analysis by gender for already completed clinical trials with adequate power and representation of women may help to explore the issue and may contribute to the hypothesis generating process, targeted clinical trials are needed. As a consequence, it was recommended that, based on the specific question addressed, clinical trials enrolling only female patients or clinical trials enrolling a significant proportion of women to

allow for prespecified gender analysis should be conducted (2).

The Policy Conference also recommended that synergic activities should be undertaken at European level with the support of national scientific societies, European institutions, national health care authorities, patients' associations and foundations. An important step was the Conference jointly organized by the European Heart Network and the European Society of Cardiology in March 2006 under the auspices of the Austrian Council Presidency, where the scientific community discussed the issues of cardiovascular diseases in women with representatives of the European Parliament, Ministries of Health of different European countries and representatives of heart foundations. During this Conference recommendations for action of the European Union to ensure that cardiovascular health for women is properly considered in all relevant European Union policies were adopted. The Conference recommended that gender-specific aspects should be promoted by the European Union and that dedicated research funding should be made available to advance gender-specific medicine.

**The Conference recommended that gender-specific aspects should be promoted by the European Union and that dedicated research funding should be made available to advance gender-specific medicine.**

## **Women and research on cardiovascular diseases: the European Heart Health Strategy (EuroHeart) project**

In 2006 the European Heart Network and the European Society of Cardiology jointly applied for a grant in the framework of the Programme of Community Action in the field of Public Health of the European Commission. The European Heart Health Strategy (EuroHeart) project was accepted for co-funding from the EU and started in April 2007. The general objective of the EuroHeart project was to address the significant burden of cardiovascular diseases in Europe and to determine

specific areas of intervention to prevent avoidable deaths and disability. Specifically, the objectives were to strengthen cross-sector cooperation (Work Package (WP) 4), obtain comprehensive comparable information on policies and actions on cardiovascular health promotion and cardiovascular disease prevention (WP 5), improve the awareness, diagnosis and treatment of cardiovascular diseases in women across Europe (WP 6), improve prevention practices at primary care level (WP 7) and implement

and adapt European guidelines on CVD prevention to national situations (WP 8). In Work Package 6, one of the specific aims of the EuroHeart project was to collect information on clinical research and to identify the gaps in knowledge of cardiovascular diseases in women in Europe.

In order to assess the current representation of women in cardiovascular research, electronic literature search of Pub Med and International Controlled Trials website has been performed. The time period covered was from 2006 (to follow up from ESC 2006 conference on women and cardiovascular diseases) to June 2009. Four different types of publications (European or international

with European representation) have been analysed: observational/epidemiological studies; randomized clinical trials, including meta-analyses, which enrolled women and men or women only; European registries, i.e. the Euro Heart Survey, on the status of clinical practice; Guidelines and Statements of European Scientific Societies.

The analysis focused on the number and percentage of women enrolled in the studies, age of participants, time of follow-up, availability of the analysis of outcomes by gender, identification of gender differences in risk, outcome or clinical practice, and inclusion of gender issues in European scientific guidelines.





# Outcome of the research

## Age, menopause and the cardiovascular risk in women

Age is an important risk factor for coronary heart disease and stroke in both genders, but women usually develop cardiovascular diseases 10 years later in life than men (2). The risk for cardiovascular diseases increases after menopause (8) partly because of ovarian hormone deficiency that favours hypertension, diabetes, hyperlipidemia, central obesity and the metabolic syndrome (2.7-9). Body weight may increase during the first year since menopause and body fat distribution changes from a gynoid (mainly to the hips and thighs) to an android pattern (mainly abdominal) (10). Central obesity increases the risk of cardiovascular events (2,11) and it is associated with other risk factors or comorbidities. In fact, the metabolic syndrome, defined by the presence of three or more risk factors which include central obesity, is more prevalent in women than in men with coronary heart disease (12).

Changes in body weight together with the activation of the renin-angiotensin-aldosterone system, associated with postmenopausal estrogens deficiency may increase arterial blood pressure. Hypertension is more prevalent in men until 45 years but after that age the reverse is true (13), and in postmenopausal women systolic and diastolic blood pressure are higher than in premenopausal women (14). Moreover, plasma cholesterol reaches the highest values between 55 and 65 years of age in women (about 10 years later than in men) (11) and menopause is associated with an increase in total and LDL cholesterol and a decline in HDL levels. Besides the metabolic effects, menopause may also contribute to the development of atherosclerosis by inducing the endothelial dysfunction (15).

Since ovarian hormone deficiency is associated with an increased risk of cardiovascular diseases, it was hypothesized that the administration of estrogens in peri- and postmenopausal women would have exerted a cardiovascular protective effect. A meta-analysis of observational studies published in 1991 (16) showed a significant reduction in the relative risk for coronary heart disease associated with

hormone replacement therapy (HRT). On this basis the Guidelines of scientific societies recommended that HRT should have been considered in all postmenopausal women to prevent coronary heart disease (17) and prescriptions of HRT rose in the 1990s. However, due to the lack of randomization, observational studies have limitations. In fact, several large controlled randomized trials subsequently performed did not confirm the reduced risk of cardiovascular diseases associated with HRT. A recent meta-analysis of 31 randomized clinical trials on 44,113 patients (18) has indeed shown that HRT is associated with an increased risk of stroke (odds ratio, OR, 1.32, 95% confidence intervals, CI, 1.14–1.53) and venous thromboembolism (OR 2.05, 95% CI 1.44–2.92), with no effect on coronary heart disease (OR 1.02, 95% CI 0.90–1.11), thus confirming a previous meta-analysis (19) (see appendix 1\*). Stroke severity was also increased with HRT (OR 1.31, 95% CI 1.12–1.54). On the basis of the results of the randomized clinical trials the Guidelines have been changed and they do not recommend HRT for the prevention of cardiovascular diseases in postmenopausal women (20-22) and prescriptions of HRT significantly declined.

Of note, the randomized clinical trials on HRT have been performed with mainly one form of hormone therapy such as combined continuous equine estrogens and medroxyprogesterone acetate or continuous equine estrogen alone (23). However, the physiological and cardiovascular effects of ovarian hormones may change with different type, dose, duration, and mode of administration, as suggested by the recent findings that transdermal estrogens, at variance with oral preparations, do not seem to be associated with increased risk of venous thrombosis (24) and that oral, but not transdermal, preparations containing estradiol markedly increase C-reactive protein (24). In the ESTHER study (25), a multicenter case-control study among postmenopausal women aged 45 to 70, venous thromboembolism occurred more frequently in current users of oral estrogens than in non-users and in transdermal estrogens users.

\* All appendices referred to in this report are available on-line on <http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>

Although obtained in a non-randomized clinical trial, these results might suggest a safer profile of transdermal as compared to oral administration of sex hormones.

The lack of beneficial cardiovascular effects observed in the randomized trials may be partly due to the age of the population and the time of beginning of therapy since menopause. In fact, an increased risk of cardiovascular diseases was found in the oldest women and in those who started HRT late after menopause began (23), although a recent analysis of the WHI trial showed that the risk may be present even soon after menopause (26). As randomized trials have shown a pattern of early harm followed by later benefit, it is possible that transient adverse effects on thrombogenesis occur in the first year after the beginning of therapy, whereas beneficial effects on cardiovascular risk factors may develop in the subsequent years (27). Further studies are necessary to assess the mechanisms underlying the detrimental or protective effects of HRT and to evaluate benefits and risks of different mode of administration, dosages and duration of HRT.

Different therapeutic approaches from HRT have been utilized in postmenopausal women. Non-hormonal interventions have not been proven to be equally effective in relieving symptoms of menopause (28). In the Raloxifene Use for The Heart (RUTH) trial (29) which enrolled 10,101 postmenopausal women (mean age, 67.5 years) with coronary heart disease or multiple risk factors for coronary heart disease, raloxifene, a nonsteroidal selective estrogen-receptor modulator that binds to the estrogens receptor, had no significant effect on the risk of coronary events (hazard ratio 0.95; 95% CI 0.84-1.07), and it reduced

the risk of invasive breast cancer (hazard ratio 0.56; 95% CI 0.38-0.83). There was no significant difference in the rates of death from any cause or total stroke, but raloxifene was associated with an increased risk of fatal stroke (hazard ratio 1.49; 95% CI 1.00-2.24) and venous thromboembolism (hazard ratio 1.44; 95% CI 1.06-1.95). Raloxifene reduced the risk of clinical vertebral fractures (hazard ratio 0.65; 95% CI 0.47-0.89). Of note, the effect of raloxifene on the incidence of coronary events differed significantly by age. A post-hoc analysis showed that the incidence of coronary events in women <60 years of age was significantly lower in those assigned raloxifene compared with placebo while no difference was found between treatment groups in the incidence of coronary events in women >60 and <70 or >70 years of age (30).

In the LIFT trial (30), a randomized study in 4,538 women with osteoporosis, aged between 60 and 85 years, tibolone, another compound which has estrogenic, progestogenic, and androgenic effects, decreased the risk of vertebral fracture (hazard ratio 0.55; 95% CI 0.41- 0.74), of nonvertebral fracture (hazard ratio 0.74; 95% CI 0.58 - 0.93), invasive breast cancer (hazard ratio 0.32; 95% CI 0.13 - 0.80) and colon cancer (hazard ratio 0.31; 95% CI 0.10 - 0.96). However, the tibolone group had an increased risk of stroke (hazard ratio 2.19; 95% CI 1.14 - 4.23), for which the study was stopped in February 2006. There were no significant differences in the risk of either coronary heart disease or venous thromboembolism between the two groups. These effects should be taken into consideration when considering the use of raloxifene or tibolone in postmenopausal women.

Thus, clear evidence on the safest hormone regimen is still lacking and there is a consensus that HRT should be prescribed for the reduction of menopausal symptoms only in younger postmenopausal women at low risk of cardiovascular diseases (15). The benefit of HRT in relieving menopausal symptoms and reducing the occurrence of hip fractures should always be weighted against the possible increased risk of cardiovascular diseases and breast cancer. As the identification of the presence of cardiovascular

**Clear evidence on the safest hormone regimen is still lacking and there is a consensus that HRT should be prescribed for the reduction of menopausal symptoms only in younger postmenopausal women at low risk of cardiovascular diseases.**



risk factors for their control in the peri- and postmenopausal women is of crucial importance, a Task Force jointly promoted by the European Society of Cardiology and the International Menopause Society published a document which recommends

the involvement of gynaecologists, who are the only physicians frequently seen by women in the absence of symptoms, for the prevention of cardiovascular diseases (32).

## Cardiovascular risk assessment and management in women

The identification and control of cardiovascular risk factors represent the basis for the development of a preventive strategy. Unfortunately, women are less likely than men to identify their risk factors and to participate in screening programmes.

**The identification and control of cardiovascular risk factors represent the basis for the development of a preventive strategy. Unfortunately, women are less likely than men to identify their risk factors and to participate in screening programmes.**

Strategies for the control of risk factors have been outlined in the Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (33). More emphasis on cardiovascular risk in women has been given in a separate session on gender issues in this updated version and the recommendations of the Policy Conference on Cardiovascular Diseases in Women have been acknowledged. The Guidelines stressed again the need to prevent all atherosclerotic cardiovascular diseases rather than just coronary heart disease, in the use of the cardiovascular risk prediction system (SCORE) (34). The SCORE charts provide means of determining the risk of dying from cardiovascular diseases in 10 years. The SCORE system is derived from data from 12 European Cohort studies that involved 205,178 individuals (93,298 women) and considers systolic blood pressure and serum cholesterol in relation to age and smoking in establishing absolute risk in either high- or low-risk European countries. As women experience cardiovascular events later in life,

in particular fatal cardiovascular events as measured by SCORE, the absolute estimated rate of risk for a perimenopausal or an early postmenopausal woman may be low when compared with men, and large increases in relative risk may not be taken into account. To avoid such problems, the SCORE system may be used to estimate the risk projected to age 60 in patients with an unhealthy risk profile but with a low absolute level of risk. Also, the SCORE system may underestimate the risk in obese patients with low HDL, increased triglycerides or impaired glucose tolerance, all features of the metabolic syndrome which is a major component of cardiovascular risk in postmenopausal women, and does not take into account diabetes, which is relatively more important as a risk factor for cardiovascular diseases in women than in men.

On the basis of this observation, the Statement of the Policy Conference on cardiovascular diseases in women (2) recommends that both the absolute risk and relative risk should be estimated, since women at low absolute risk may carry a high relative risk. Risk factors that are particularly important for women, i.e. diabetes and obesity, should be taken into account. Risk should be extrapolated to a higher age in women (70 years instead of 60 years).

**Risk factors that are particularly important for women, i.e. diabetes and obesity, should be taken into account. Risk should be extrapolated to a higher age in women (70 years instead of 60 years).**

In order to improve cardiovascular risk stratification in women some recent studies assessed new score

systems and novel markers. A study performed in the United States in approximately 25,000 healthy women age 45 and older, followed up for a median of 10.2 years tested a new risk algorithm, named Reynolds Risk Score (35). Two new variables, such as parental family history of premature coronary heart disease and high-sensitivity C-reactive protein (hsCRP), were added to the variables in the ATP-III risk score. At variance with the European SCORE system and similarly to the Framingham score, the outcome was not cardiovascular death but cardiovascular events, although stroke has been added to coronary heart disease. With this score system women were classified into higher- or lower-risk categories with improved accuracy compared with the currently used risk prediction model in the United States.

In the Nurses' Health Study which enrolled 121,700 women, plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a marker utilized for risk stratification in heart failure patients, have been found to predict risk of sudden cardiac death, after adjustment for coronary heart disease risk factors and other biomarkers (36).

Other markers, as plasma homocysteine, have been found to be associated with a higher risk of ischemic heart disease and stroke, but its reduction induced by the administration of folic acid, vitamin B12 or vitamin B6 in randomized clinical trials did not show any benefit (37,38).

Epidemiological studies have been performed to test the changes in the prevalence of risk factors and the adherence to the recommendations of Scientific Guidelines for risk control. The third EUROASPIRE survey was done in 2006–07 in 22 European countries to assess whether preventive cardiology had improved and if the Joint European Societies' recommendations on cardiovascular disease prevention are being followed in clinical practice (39). Data of this survey have been compared with those of the second and first EUROASPIRE surveys. Although the overall proportion of patients who smoke has remained almost the same (20.3% in EUROASPIRE I, 21.2% in II, and 18.2% in III), the

proportion of women smokers aged under 50 has significantly increased. The frequency of obesity (body-mass index  $\geq 30$  kg/m<sup>2</sup>) increased in both sexes from 25.0% in EUROASPIRE I, to 32.6% in II, and 38.0% in III ( $p=0.0006$ ), as well as the frequency of self-reported diabetes mellitus which increased from 17.4%, to 20.1%, and 28.0% ( $p=0.004$ ). The proportion of patients with raised blood pressure ( $\geq 140/90$  mm Hg in patients without diabetes or  $\geq 130/80$  mm Hg in patients with diabetes) was unchanged whereas the proportion with raised total cholesterol decreased from 94.5% in EUROASPIRE I to 76.7% in II, and 46.2% in III ( $p<0.0001$ ). However, while 43.3% of men have increased levels of total cholesterol in the last survey, the percentage of women with raised cholesterol is still 55.7%.

These time trends show a compelling need for more effective lifestyle management in both genders and a special effort for preventing smoking initiation and favouring smoking cessation in young women. The risk of cardiovascular diseases is indeed particularly high if smoking starts before the age of 15 (40). Furthermore, the mortality from cardiovascular diseases is higher in women who smoke than in men who smoke (41,42), even after adjustment for other risk factors. It has been shown that women metabolize nicotine faster than men, especially when taking oral contraceptives (43). Smoking and oral contraceptives exert synergistic effects on the risk of cardiovascular diseases (44). In a meta-analysis of studies on the effects of smoking cessation after myocardial infarction, mortality was reduced by 46% (Odd ratio 0.54, 95% CI 0.46-0.62), and the effect was consistent regardless of gender (45).

**Mortality from cardiovascular diseases is higher in women who smoke than in men who smoke, even after adjustment for other risk factors. It has been shown that women metabolize nicotine faster than men, especially when taking oral contraceptives. Smoking and oral contraceptives exert synergistic effects on the risk of cardiovascular diseases.**



## Gender and blood pressure-lowering treatment

Large-scale observational studies show that lower blood pressure is associated with lower cardiovascular risk in both men and women, although some studies have suggested that different outcomes between the sexes may reflect different responses to blood pressure-lowering treatment (46-48). The trials on blood pressure-lowering treatment performed since 2006 showed that there is a fair representation of women in these studies (49-54) (see appendix 2\*). Overall, 5 randomized controlled trials enrolled 69,473 patients and 28,008 were women (40.3%). Mean age of participants was 70.2 years and the mean follow-up was 3.2 years. The percentage of women enrolled in each trial varies between 27% and 60%. However, prespecified analysis by gender was present in the primary publication only in 3 of these 5 trials. No significant gender differences were found in the trials which reported the analysis separated in women and in men.

Recently, a meta-analysis of clinical trials on blood pressure-lowering treatment has been performed with the aim to quantify the effects in each sex and to determine if there are important differences in the proportional benefits of treatment between men and women (55). Thirty-one randomized trials that included 103,268 men and 87,349 women contributed to these analyses. Achieved blood pressure reductions were comparable for men and women in every comparison made. Although women experienced fewer events than men, for the primary outcome of total major cardiovascular events there was no evidence that men and women obtained different levels of protection from blood pressure-lowering or that regimens based on angiotensin-converting-enzyme inhibitors, calcium antagonists, angiotensin receptor blockers, or diuretics/ beta-blockers were more effective in one sex than the other. Thus, all of the blood pressure-lowering regimens studied provided broadly similar protection against major cardiovascular events in men and women. Differences in cardiovascular risks between sexes are unlikely to reflect differences in response to blood pressure-lowering treatments.

These observations are similar to the results of a previous meta-analysis of randomized, controlled trials, provided by the INDANA (Individual Data Analysis of Antihypertensive intervention trials) Investigators (56), and based on seven trials that included 20,802 women and 19,975 men recruited between 1972 and 1990.

The most recent Guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) released in 2007 (57) addressed the specific issue of treatment of hypertension in women. The Guidelines stated that the response to antihypertensive agents and the beneficial effects of blood pressure lowering appear to be similar in women and in men. However, the adherence to blood pressure lowering therapy is far less than ideal in both women and men. It has been shown that in Europe less than 50% of hypertensive patients are treated, and among these about 50% do not reach the level of blood pressure suggested by the Guidelines. Furthermore, the Guidelines stated that even low oestrogen oral contraceptives are associated with increased risk of hypertension, stroke and myocardial infarction. The progestogen-only pill is a contraceptive option for women with high blood pressure, but influence on cardiovascular outcomes has been insufficiently investigated.

The European Guidelines addressed also the important issue of hypertensive disorders in pregnancy, particularly pre-eclampsia, which may adversely affect neonatal and maternal outcomes. Recommendations on the levels of blood pressure which deserve non-pharmacological or pharmacological treatment and the specific drugs indicated in these conditions have been provided. ACE inhibitors and angiotensin receptor antagonists should be avoided in pregnant and pregnancy planning women because of potential teratogenic effects of these agents.

The recently published European Society of

\* Available on-line on

<http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>

Hypertension Guidelines for blood pressure monitoring at home (58) included a chapter on the measurements in pregnant women. Home blood pressure measurement, although at present not commonly practised in this setting, has considerable potential in improving the management of pregnant women. However, few devices have been validated in pregnancy by methodologically acceptable studies.

It is also important to consider that women with previous gestational hypertension are at increased risk for cardiovascular diseases in later life (59,60). This may depend on a relative hyperandrogenic state but also on alterations in endothelial function, carbohydrate and lipid metabolism, which have been shown in otherwise healthy women with previous gestational hypertension. Accordingly, women who experienced hypertensive disorders during pregnancy should receive a strict follow-up in order to identify those who may develop hypertension later in their life.

**Women who experienced hypertensive disorders during pregnancy should receive a strict follow-up in order to identify those who may develop hypertension later in their life.**





## Diabetes and the metabolic syndrome in men and women

Since 2006 clinical trials performed in patients with diabetes enrolled a fair percentage of women, but the impact of sex differences on the reported results were rarely assessed (61-68) (see appendix 3\*). Overall, 7 randomized clinical trials enrolled 48,508 patients and 20,091 were women (41.4%). Mean age of participants was 61.1 years and mean follow-up was 4.3 years. The percentage of women enrolled in each trial ranges between 30 and 59%. Four out of 7 trials (57.1%) reported the analysis of the results by gender. Existing studies, however, reveal several differences between men and women with diabetes. The risk of coronary heart disease mortality associated with diabetes is higher in women than in men. Women with diabetes, regardless of menopausal status, have a 4- to 6-fold increase in the risk of developing coronary artery disease, whereas men with diabetes have a 2- to 3-fold increase in risk (9). Furthermore, women with diabetes have a poorer prognosis after myocardial infarction and a higher risk of death from cardiovascular diseases than men with diabetes. The prevalence of the metabolic syndrome is increasing in both sexes, but has risen particularly in young women, where it is mainly driven by obesity (9).

**Women with diabetes, regardless of menopausal status, have a 4- to 6-fold increase in the risk of developing coronary artery disease, whereas men with diabetes have a 2- to 3-fold increase in risk.**

**Furthermore, women with diabetes have a poorer prognosis after myocardial infarction and a higher risk of death from cardiovascular diseases than men with diabetes. The prevalence of the metabolic syndrome is increasing in both sexes, but has risen particularly in young women, where it is mainly driven by obesity.**

Women may have an additional risk factor for developing diabetes, represented by gestational diabetes. Gestational diabetes is defined as carbohydrate intolerance of any degree that begins or is first recognised during pregnancy. The risks of gestational diabetes, which complicates about 3-5% of pregnancy, include neonatal macrosomia and increased rates of caesarean delivery (69). Moreover, it has been recently shown that gestational diabetes, as well as prepregnancy diabetes, is independently associated with perinatal depression, including new onset of postpartum depression, in low-income new mothers (70).

Additionally, the effects of gestational diabetes after pregnancy, also in the long-term, have been acknowledged (71). In fact, women with gestational diabetes are at increased risk of developing type 2 diabetes, but risk and time of onset has not been fully quantified. A recent comprehensive systematic review and meta-analysis of 20 studies that included 675,455 women and 10,859 type 2 diabetic events, has assessed the strength of association between gestational diabetes and type 2 diabetes and the effect of factors that might modify the risk (72). Women with gestational diabetes had an increased risk of developing type 2 diabetes compared with those who had a normoglycaemic pregnancy (RR 7.43, 95% CI 4.79–11.51). Thus, increased awareness of the magnitude and timing of the risk of type 2 diabetes after gestational diabetes among patients and clinicians could provide an opportunity to test and use dietary, lifestyle, and pharmacological interventions that might prevent or delay the onset of type 2 diabetes in affected women.

The 2007 Guidelines on diabetes, pre-diabetes and cardiovascular diseases of the European Society of Cardiology and the European Association for the Study of Diabetes (9) addressed the issue of diabetes and the metabolic syndrome in women. The Guidelines stated that women with glucometabolic perturbations carry a particularly high risk for cardiovascular morbidity and mortality,

\* Available on-line on

<http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>

and recommend that in this respect they need special medical attention. Adequate control of blood pressure with antihypertensive agents and of cholesterol with statins have proven to be effective in reducing cardiovascular risk in both men and women with diabetes. Control of glycaemia reduces microvascular events, with a lower impact on macrovascular events, regardless of gender. Two recent trials demonstrated that even an intensive glucose control does not reduce the occurrence of major cardiovascular events and this is true for both men and women (65,66). A meta-analysis of 5 prospective randomised controlled trials of 33,040 participants (73) showed that intensive, compared with standard glycaemic control significantly reduces coronary events but not stroke.

However, women seem to be more prone to the adverse effects of some hypoglycaemic agents. A recent meta-analysis of 10 randomized controlled trials involving 13,715 participants and from 2 observational studies with 31,679 subjects showed that long-term thiazolidinediones use doubles the risk of fractures among women with type 2 diabetes, but not among men (74). A gender

difference in the occurrence of adverse effects with this class of glucose-lowering agents was recently confirmed by the RECORD trial (68), in which therapy with rosiglitazone was associated with a higher incidence of distal lower limb fractures in women and not in men. Thiazolidinediones exposure was also associated with significant changes in bone mineral density at the lumbar spine and the hip. Thiazolidinediones may cause fractures by increasing adiposity of bone marrow, decreasing osteoblast activity or reducing aromatase activity which alters estrogens production and increases bone resorption. However, the underlying mechanism for the possible sex-specific effect of thiazolidinediones needs further investigation. Thus, the choice of the type of hypoglycaemic agents in women should take into consideration this potential increased risk of side effects. The recent consensus documents of the American Diabetes Association and the European Association for the Study of Diabetes advised (75) against the use of rosiglitazone and recommend caution in using the other thiazolidinediones for the risk of heart failure (76) in both men and women. They also recommend caution in their use in women because of the higher risk of fractures.

## **Cholesterol-lowering therapy and cardiovascular prevention in men and women**

Blood cholesterol is a risk factor for cardiovascular diseases in both women and men. Statins have been demonstrated to reduce the risk of coronary artery disease and stroke in trials mainly performed in patients who already had a cardiovascular event or are at very high risk. Until recent years the evidence for a beneficial effect of statins in primary prevention, i.e. in people who did not have a cardiovascular event or are at low risk was less clear. Since 2006, six randomized clinical trials of primary or secondary prevention with statins have been performed (77-83) (see appendix 4\*). A total of 50,194 patients of which 15,036 women (30%) have been enrolled and the percentage of women in each trial varies between 19% and 50%. Mean age of participants was 60.8 years and mean follow-up was 3.2 years. Of note, only one of these 6 trials reported the analysis

of the results by gender in the primary publication and significant differences in the outcomes between women and men have not been shown.

A meta-analysis of data from 90,056 individuals in 14 randomized trials of secondary and primary prevention demonstrated that statin therapy can significantly and safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke, largely irrespective of the initial lipid profile (84). The absolute benefit was greater in patients at high cardiovascular risk and depended on the absolute reduction in LDL cholesterol achieved. Overall, the clinical trials included in this meta-analysis enrolled 21,575 women (24%). Although the number of events was lower in women than in men (7.3% vs. 10.6%) the benefit of statins was similar (18

\* Available on-line on  
<http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>



vs. 24% reduction in the events in women and men respectively, with a non-significant heterogeneity test). An updated meta-analysis published in 2009, which included also the most recent trials, confirmed these findings (85).

However, another meta-analysis which included only statins trials of primary prevention showed that the risk reduction was somewhat lower in women than in men (86). This meta-analysis was done in a population of 19,052 women and 30,194 men before the publication in 2008 of the largest trial performed with statins in individuals free of cardiovascular diseases, the JUPITER trial (82).

Statins lower cholesterol but also high-sensitivity C-reactive protein, an inflammatory biomarker that predicts cardiovascular events if its levels are increased. Accordingly, the JUPITER trial (82) was performed in 17,802 men and women without history of cardiovascular disease with normal LDL cholesterol and high-sensitivity C-reactive protein levels of 2.0 mg per litre or higher, randomized to rosuvastatin, 20 mg daily, or placebo and followed for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. It is interesting to note that in order to obtain a similar proportion of events in women and in men a different minimum age was established among the inclusion criteria. In fact, whereas the 11,001 men enrolled were 50 years of age or older, the 6,801 women were 60 years of age or older. The trial was prematurely stopped after a median follow-up of 1.9 years because of an excess of events in the placebo arm. Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval 0.46 to 0.69;  $P < 0.00001$ ). Consistent effects were observed in all subgroups evaluated. Specifically, the relative hazard reductions in the rosuvastatin group were similar for women (46%) and men (42%). Thus, in

this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. Of note, the apparent lower beneficial effect in women compared with men, observed in the previous meta-analysis, was not confirmed in this large primary prevention trial which included a number of women representing almost one third of those enrolled in all the other previous trials combined. In fact, a most recent meta-analysis on 10 trials which enrolled a total of 70,388 people without established cardiovascular disease but with cardiovascular risk factors, of whom 23,681 (34%) were women and which included the JUPITER trial, showed that statin use was associated with significantly improved survival and large reductions in the risk of major cardiovascular events in both women and men (87).

**A most recent meta-analysis on 10 trials which enrolled a total of 70,388 people without established cardiovascular disease but with cardiovascular risk factors, showed that statin use was associated with significantly improved survival and large reductions in the risk of major cardiovascular events in both women and men.**

The European Guidelines for cardiovascular disease prevention released in 2007 (33) recommend statins for men and women who had a coronary or a cerebrovascular event, and in primary prevention for men and women with high levels of LDL cholesterol or at high risk for cardiovascular diseases, i.e. diabetes. They also emphasize the role of diet and physical activity in reducing cardiovascular risk.

## Aspirin for secondary and primary prevention: Do gender differences exist?

There is compelling evidence that aspirin reduces morbidity and mortality in patients who already had a cardiovascular event (88-89). For this reason all the Guidelines recommend the use of aspirin in patients with ischemic heart disease, cerebrovascular disease or peripheral artery disease for secondary prevention. In a recent meta-analysis of 16 secondary prevention trials involving 17,000 individuals at high average risk, the Antithrombotic Trialists' investigators (88) compared the effects of long-term aspirin versus control on myocardial infarction, stroke, or vascular death (see appendix 5\*). Aspirin allocation yielded an absolute reduction in serious vascular events (6.7% vs. 8.2% per year,  $p < 0.0001$ ). Specifically, aspirin induced reductions in coronary events (4.3% vs. 5.3% per year,  $p < 0.0001$ ) and in total stroke (2.08% vs. 2.54% per year,  $p = 0.002$ ), with a non-significant increase in haemorrhagic stroke. These effects were similar in men and women.

The effects of aspirin in primary prevention, i.e. in subjects who did not have a cardiovascular event, are less clear. A previous meta-analysis was performed with the aim to determine if the benefits and risks of aspirin treatment in the primary prevention of cardiovascular diseases vary by sex (90). The effects of aspirin on the occurrence of myocardial infarction, stroke or cardiovascular mortality were assessed in 6 trials involving 95,456 individuals without cardiovascular disease; 3 trials included only men, 1 included only women, and 2 included both sexes. Among 51,342 women aspirin therapy was associated with a significant 12% reduction in cardiovascular events (odds ratio, 0.88; 95% confidence interval (CI), 0.79-0.99;  $P = 0.03$ ). This effect was driven by a 17% reduction in stroke (OR, 0.83; 95% CI, 0.70-0.97;  $P = 0.02$ ), which was a reflection of reduced rates of ischemic stroke (OR, 0.76; 95% CI, 0.63-0.93;  $P = 0.008$ ). There was no significant effect on myocardial infarction or cardiovascular mortality. Among 44,114 men aspirin therapy was associated with a significant 14% reduction in cardiovascular events (OR, 0.86; 95% CI, 0.78-0.94;  $P = 0.01$ ) but, at variance with the findings in women, this effect was driven by a 32% reduction

in myocardial infarction (OR, 0.68; 95% CI, 0.54-0.86;  $P = 0.001$ ) with no significant effect on stroke or cardiovascular mortality. Aspirin treatment increased the risk of bleeding in women (OR, 1.68; 95% CI, 1.13-2.52;  $P = 0.01$ ) and in men (OR, 1.72; 95% CI, 1.35-2.20;  $P < 0.001$ ). Thus, it appears that aspirin exerts different effects in the prevention of myocardial infarction and stroke in men and women.

The most recent meta-analysis performed by the Antithrombotic Trialists' investigators (88) analyzed the same 6 trials of primary prevention, with the difference that they had access to individual participant data, which allowed the investigators to estimate the magnitude of several risk factors for selected outcomes. The overall results were similar but, at variance with the aggregate meta-analysis described above the proportional reduction in specific vascular outcomes did not differ significantly between men and women when adjustment for multiple comparisons was made.

It is interesting to note, however, that the 2009 update of the U.S. Preventive Services Task Force (USPSTF) recommendation statement encourages men age 45 to 79 years to use aspirin for the reduction in myocardial infarctions and women age 55 to 79 years for the reduction in ischemic strokes, if these effects outweigh the potential harm of an increase in gastrointestinal haemorrhages (91). It also states that the evidence is insufficient to assess the balance of benefits and harms of aspirin for cardiovascular disease prevention in men and women 80 years or older.

The 2007 Guidelines for management of ischemic stroke and transient ischemic attack of the European Stroke Organization (92) recommend low-dose aspirin for primary prevention of stroke in women aged 45 years or more who are not at increased risk for intracerebral haemorrhage and who have good gastro-intestinal tolerance, although its effect is very small.

The 2007 European Guidelines for cardiovascular

\* Available on-line on <http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>



disease prevention (33) recommend aspirin for men and women with established cardiovascular disease and diabetes, unless contraindicated. For primary prevention in asymptomatic individuals aspirin should be considered only when the 10-year risk

of cardiovascular mortality is markedly increased and blood pressure well controlled, irrespective of gender.

## Gender differences in ischemic heart disease

Clinical research on coronary heart disease since 2006 has included a lower proportion of women than their male counterpart (93-108) (see appendix 6\*). Overall, 13 randomized clinical trials enrolled 90,400 patients and only 24,756 were women (27.3%). Mean age was 62.6 years and mean follow-up of the studies was 0.9 years, shorter than in the other trials because they mainly assessed the effects of treatments in the acute coronary syndromes and the outcome occurred in the first months after enrolment. The percentage of women enrolled in each trial ranges from 19.0% to 34.6% and 5/13 trials (38.4%) reported the analysis of the results by gender. Some meta-analysis of ischemic heart disease studies do not even report the number of percentage of women enrolled (109,110). However, in order to address specific issues related to coronary heart disease in women, there have been some studies conducted exclusively in women.

**Clinical research on coronary heart disease since 2006 has included a lower proportion of women than their male counterpart.**

Gender differences in the clinical manifestation of coronary heart disease have been shown in several studies. Women tend to present with atypical symptoms such as abdominal pain, dyspnoea, nausea and fatigue (111) more often than men. As coronary heart disease develops in women later in life than in men, the symptoms of a heart attack may be masked by other diseases (112). Furthermore, women have a higher prevalence of silent ischemia (113) and of unrecognized myocardial infarction than men (114).

A systematic review and meta-analysis of international variations across 31 Countries (115) recently assessed the prevalence of angina in men and women by using the Rose questionnaire and the myocardial infarction mortality rates from the World Health Organization. A total of 74 reports of 13,331 angina cases in women and 11,511 cases in men were included. Angina prevalence varied widely across populations, from 0.73% to 14.4% (population weighted mean 6.7%) in women and from 0.76% to 15.1% (population weighted mean 5.7%) in men. Angina prevalence showed a small female excess with a pooled random-effects sex ratio of 1.20 (95% CI 1.14 to 1.28,  $P < 0.0001$ ). Thus, over time and at different ages, independent of diagnostic and treatment practices, women have a similar or slightly higher prevalence of angina than men across countries with differing myocardial infarction mortality.

It has been shown that some diagnostic tests and procedures may not be as accurate in women and physicians may avoid using them leaving some women with undetected coronary heart disease, which may lead to more serious consequences for the delay in the diagnosis (116). Gender differences in the results of diagnostic testing should be taken into account in clinical practice. Exercise stress testing, commonly used to diagnose ischemic heart disease, may be less accurate in women and may give a false positive result (117-119), especially in young women with a low likelihood of coronary heart disease. However, as exercise testing carries a high negative predictive value, it is widely available and at low costs. Guidelines recommend to perform ECG stress test as first diagnostic procedure, also for women. In case of abnormal ECG stress test,

\* Available on-line on

<http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>

stress echocardiography is the test with the higher sensitivity and specificity. In women not suitable for stress echocardiography or who are not able to exercise, radionuclide myocardial perfusion or MRI is a reasonable option. Cardiac CT angiography may be a useful tool for women with non-conclusive stress tests, while coronary angiography is indicated in case of abnormal or unclear non-invasive imaging tests (120).

Women with clinical findings suggestive of ischemia but without obstructive coronary artery disease on angiography represent a frequent clinical problem. In the Women's Ischemia Syndrome Evaluation (WISE) study (121) performed in women with suspected ischemia but no angiographic evidence of obstructive coronary artery disease, the 5-year cardiovascular events were 16.0% in those with a stenosis in any coronary artery of 1%-49% and 7.9% in symptomatic women with normal coronary arteries. In 1,000 asymptomatic age- and race-matched women, cardiovascular events occurred in 2.4% ( $P=0.002$ , after adjusting for baseline risk factors). Thus, women with symptoms and signs suggestive of ischemia, but without obstructive coronary artery disease, are at elevated risk for cardiovascular events compared with asymptomatic women (121). A tool for the identification of higher risk of events in this particular population of symptomatic women without obstructive coronary artery disease may be an invasive testing of coronary vasoreactivity which allows exclusion or verification of endothelial dysfunction and coronary spasm. Moreover, invasive or non-invasive determination by Positron Emission Tomography (PET) of the coronary flow reserve enables assessment of the functional status of the microvasculature, although these procedures are rarely available (120).

**Women were less likely to undergo an exercise ECG test and less likely to be referred for coronary angiography.**

The impact of gender on the investigation and subsequent management of stable angina and the

assessment of gender differences in clinical outcome at 1 year has been analyzed in the Euro Heart Survey of Stable Angina (122). A total of 3,779 patients were included in the survey; 42% were female. Women were less likely to undergo an exercise ECG test (odds ratio, 0.81; 95% CI, 0.69 to 0.95) and less likely

**Antiplatelet and statin therapies were used significantly less in women than in men, both at initial assessment and at 1 year, even in those in whom coronary disease had been confirmed.**

to be referred for coronary angiography (odds ratio, 0.59; 95% CI, 0.48 to 0.72). Antiplatelet and statin therapies were used significantly less in women than in men, both at initial assessment and at 1 year, even in those in whom coronary disease had been confirmed. Women with confirmed coronary disease were less likely to be revascularized than their male counterparts and were twice as likely to suffer death or nonfatal myocardial infarction during the 1-year follow-up period (hazard ratio, 2.09; 95% CI, 1.13 to 3.85), even after multivariable adjustment for age, abnormal ventricular function, severity of coronary disease, and diabetes. The Euroheart study showed that significant gender differences were identified in the use of investigations and of evidence-based medical therapy in stable angina. This is of particular concern in light of the adverse prognosis observed among women with stable angina and confirmed coronary disease. Further research is needed to elucidate the reasons for the adverse prognosis observed in women with stable angina and proven coronary disease.

**Women with confirmed coronary disease were less likely to be revascularized than their male counterparts and were twice as likely to suffer death or nonfatal myocardial infarction during the 1-year follow-up period, even after multivariable adjustment for age, abnormal ventricular function, severity of coronary disease, and diabetes.**



The 2006 Guidelines on stable angina of the European Society of Cardiology (123), included a chapter on the impact of the disease in women and recommended that they should have the same access to coronary angiography as men. They also

stated that limited female representation in clinical trials of secondary prevention is not a justification to apply guidelines differently to women and men after diagnosis of coronary artery disease.

### **Acute coronary syndromes and coronary revascularization from a gender perspective**

Gender differences in the manifestation of acute coronary syndromes, including ST-elevation myocardial infarction, non-ST elevation myocardial infarction and unstable angina have been demonstrated (124). As women develop coronary heart disease later than men the average age of women with non-ST-elevation-acute coronary syndromes (NSTEMI-ACS) was 6 years higher than in men (71 vs. 65 years) (125). As a consequence, 45% of females and 20% of males were older than 75. Diabetes was more frequent in females than in males (26 vs. 22%). Of note, in a registry of 201,114 patients (126) with a first myocardial infarction, multivariate analysis showed that younger women had a 25% higher 30-day mortality compared with men. However, gender was not an independent predictor of survival at 1-year. Interactions between age and gender observed in short-term case fatality can be explained by increased pre-hospital mortality in men. However, among older women and men, the mortality rates were similar after adjustments for co-morbid illnesses. Also in the analysis from the GUSTO-2B trial, women with NSTEMI-ACS had a significantly higher mortality rate at 30 days than men, but similar rates of re-infarctions (127). As for stable angina, females with NSTEMI-ACS are less likely to receive evidence based diagnostic procedures and therapies (128).

Recently, the benefits and risks of an early invasive strategy with coronary angiography (and if appropriate, coronary revascularization within 7 days) compared with a selective invasive strategy (with coronary angiography only if symptoms or signs of severe ischemia occurred) in women with non-ST-elevation acute coronary syndromes have been assessed in a sub-study of the OASIS-5 trial (129). There were no significant differences between

the two treatment strategies in the primary outcome of death, myocardial infarction or stroke, but higher 1-year mortality and a higher rate of major bleeding at 30 days in women of the early invasive strategy group. Similarly, a meta-analysis including 2,692 women in previous randomized trials, showed no significant difference in the outcome of death or myocardial infarction, but a higher mortality with an early invasive strategy for women. Unlike in men, when combined with data from previous trials, there does not appear to be a benefit of an early invasive strategy in women with acute coronary syndromes. Another sub-study of the OASIS-5 trial, the TIMACS trial (107), showed that a very early invasive strategy (within 24 hours after randomization) did not differ from delayed intervention in preventing the primary outcome in low-risk patients, but was superior to delayed intervention in high-risk patients. The risk of events in this sub-study with early intervention was consistent in women and men. Thus, if an invasive strategy is selected for women with acute coronary syndromes, there does not appear to be harm if the intervention is performed very early in high-risk patients, similarly to what has been shown in a previous meta-analysis (130). On the basis of these somewhat conflicting results, large-scale randomized trials in women are needed in order to determine the most appropriate strategy in the management of acute coronary syndromes.

Gender differences in patients undergoing coronary revascularization procedures have been reported. Despite a higher prevalence of additional risk factors, women undergoing by-pass surgery show a similar outcome to men (131). It has been shown at cardiac catheterization that women have smaller coronary arteries (132) and that the vessel size influences device utilization for percutaneous

revascularization with a lower use of endovascular stents (133). The risk of adverse events during and after the procedures, including coronary dissection and peripheral local bleeding, is greater in women than in men. The success rate of percutaneous revascularization (PCI) is similar in men and women (134), as well as the effects of new antithrombotic agents as concomitant therapy and the reduction in restenosis with the wider use of drug-eluting stents (135, 136). An analysis of gender impact on outcomes in patients undergoing percutaneous coronary intervention using sirolimus-eluting stents (SES), has shown that, despite less favourable baseline clinical and angiographic features in women compared with men, the angiographic and clinical benefits of SES were similar (137). However, in European registries, women were under-treated compared with men, especially with PCI (24.4% for men vs. 22.9% for women), prescription of clopidogrel (49% for men vs. 39% for women), and prescription of GP IIb/IIIa inhibitors (24.8% for men vs. 23.8% for women) (125-128, 138-139). Referral for percutaneous or surgical revascularization was significantly lower for women. For most treatments, there was no gender differential treatment effect with new therapeutic agents (140,141). However, with GP IIb/IIIa inhibitors, several trials have reported more adverse events in women, especially in those at lower risk. Indeed, it has been shown that women experience more bleeding than men whether or not they are treated with GP IIb/IIIa inhibitors (142). As excessive dosing in women takes place frequently, it may be considered that up to one fourth of this sex-related risk difference in bleeding is avoidable. Appropriate dosing should improve care of all patients with NSTEMI-ACS, with a particular benefit for women.

The 2007 Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology (143) recommend that women be evaluated and treated similarly to men, with special attention to comorbidities. The 2008 Guidelines for the Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation (144) did not include any specific recommendation related to gender.

## Gender differences in heart failure

Heart failure is the most common cardiovascular cause of hospital admission in both men and women. However, gender differences in the manifestation of heart failure have been demonstrated (145). More men than women suffer from heart failure at younger ages, but after the age of 75 the reverse is true, as more women are affected by heart failure, especially with normal left ventricular ejection fraction (146). With the increase of life expectancy, which is greater in women than in men, the proportion of older women with heart failure is expected to increase further in the future.

**More men than women suffer from heart failure at younger ages, but after the age of 75 the reverse is true, as more women are affected by heart failure, especially with normal left ventricular ejection fraction.**

**With the increase of life expectancy, which is greater in women than in men, the proportion of older women with heart failure is expected to increase further in the future.**

In the past, most large, multicenter trials have not included sufficient numbers of women to allow for conclusions on the efficacy and safety of their treatment. Since 2006 the proportion of women enrolled in clinical trials on heart failure did not significantly increase (147-161) (see appendix 7\*). Overall 11 randomized clinical trials enrolled 46,141 patients and 12,834 were women (27.8%). Mean age was 69.2 years and mean follow-up 2.4 years. The percentage of women enrolled in each trial ranges from 15% to 60%. Despite this variable proportion of women, the majority of the trials (8/11; 72.7%) reported the analysis of the results by gender.

The analysis of previous trials suggested gender differences in the efficacy of some therapeutic agents. A post-hoc analysis of the DIG trial showed that women with heart failure who received digoxin

\* Available on-line on <http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>



had a higher mortality than those receiving placebo (162), an effect that was not observed in men and that may depend on a higher percentage of women with drug plasma levels above the therapeutic range due to a lower renal clearance of digoxin (163). It has also been suggested that women with heart failure, particularly with asymptomatic reduced left ventricular ejection fraction (LVEF), may not show survival benefits from ACE inhibition (164,165). Women may also have a different safety profile than men, as evidenced by their higher risk of ACE inhibitors-induced cough (165). However, in the most recent trials which reported the results by gender, the effects of main interventions were similar in men and women with heart failure. The recent MADIT-CRT trial demonstrated that cardiac resynchronization therapy combined with ICD decreased the risk of heart-failure events in relatively asymptomatic patients with a low ejection fraction and wide QRS complex and that the beneficial effect was significantly greater in women than in men (167).

There are studies that have assessed the association between gender and clinical characteristics, outcome and management of heart failure. An analysis from 8,791 men and 2,851 women with systolic dysfunction, randomized in 5 clinical trials (168), showed that, irrespective of aetiology, women were older, smoked less often or had prior myocardial infarctions, but had higher systolic blood pressures, more diabetes, and more severe symptoms than men. However, women had better outcomes (all-cause mortality or all-cause hospitalization) than men. Similar results in terms of outcomes have been obtained with an analysis of 2,400 women and 5,199 men randomized in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (150). This trial enrolled also heart failure patients with a normal ejection fraction that was more frequent in women (50%) than in men (35%). An ischemic cause of heart failure was less frequent in women (51%) than in men (67%). All-cause mortality was 21.5% in women and 25.3% in men and fewer women (30.4%) than men (33.3%) experienced cardiovascular death or heart failure hospitalization, independently of LVEF or aetiology of heart failure.

The Euroheart Survey on heart failure performed in Europe (169) found that among a total of 8,914 patients (47% women) with confirmed diagnosis of heart failure, women were older (74.7 vs. 68.3 years,  $p < 0.001$ ), less often had evidence of coronary artery disease (56% vs. 66%), were more likely to have hypertension, diabetes, or valvular heart disease. However, at variance with the randomized trials, in this survey which reflects the clinical practice, 12-week mortality was similar for men and women. Indeed, gender differences in the management of heart failure may have contributed to influence the outcome. In fact, fewer women had an investigation of left ventricular function (59% vs. 74%, age-adjusted OR 0.67; 95% CI 0.61 to 0.74) and were treated with drugs with a documented impact on survival, that is ACE-inhibitors and beta-blockers (OR 0.72; 95% CI 0.61 to 0.86 and OR 0.76; 95% CI 0.65 to 0.89, respectively). Furthermore, an observational study on 13,034 patients with heart failure and left ventricular ejection fraction  $< 30\%$ , reported that among potentially eligible patients, fewer women than men received implantable cardioverter-defibrillator (ICD) therapy (170). Thus, women with heart failure appear to be less often investigated and treated with evidence-based drugs, even after adjustment for age and important clinical characteristics.

**Women with heart failure appear to be less often investigated and treated with evidence-based drugs, even after adjustment for age and important clinical characteristics.**

The 2008 Guidelines for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (171) do not include gender related issues. However, they provide a recommendation for pregnancy, stating that this condition may lead to deterioration of heart failure due to the rise in blood volume and increase in cardiac output, as well as the substantial increase in extra vascular fluid. Importantly, many medications used in heart failure treatment are contra-indicated during pregnancy. As the risk

of pregnancy is considered greater than the risks linked to contraceptive use, it is recommended that women with heart failure discuss contraceptives and planned pregnancy with a physician in order

to take an informed decision based on assessment of potential risks.

## Gender and atrial fibrillation

Atrial fibrillation is the most common arrhythmia encountered in clinical practice, accounting for approximately one third of all hospitalizations for cardiac rhythm disturbances (172). The prevalence of atrial fibrillation is 0.4% to 1% in the general population (173), and increases with age to 8% in patients older than 80 (174). The median age of patients with atrial fibrillation is about 75 years, but approximately 60% of those over 75 are female. In a large cohort of 34,221 initially healthy women participating in the Women's Health Study (174) blood pressure, especially systolic blood pressure, was strongly associated with incident atrial fibrillation.

Atrial fibrillation is associated with an increased long-term risk of stroke (172,176), heart failure, and all-cause mortality, especially among women (172). The Stroke Prevention in Atrial Fibrillation (SPAF) study (177), and the Framingham study (178) found that women with atrial fibrillation are at greater risk of stroke, but antithrombotic therapy is equally effective in both genders (179).

**Atrial fibrillation is associated with an increased long-term risk of stroke, heart failure, and all-cause mortality, especially among women.**

Clinical trials on the treatment of atrial fibrillation and on the prevention of stroke enrolled a fair proportion of women (180-188) (see appendix 8\*). Overall, 7 randomized clinical trials enrolled 28,790 patients of which 10,618 were women (36.9%). The mean age was 69.0 years and the mean follow-up 2.3 years. The percentage of women enrolled in each trial ranges from 23.3% to 56.6% and 3/7 trials (42.8%) reported the analysis of the results

by gender. No gender differences in the outcomes have been observed.

Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation have been demonstrated in Europe. A report from the Euro Heart Survey on atrial fibrillation (189) in 5,333 patients (42% female) showed that compared with men, women were older, had a lower quality of life (QoL), had more comorbidities, more often had heart failure with preserved left ventricular systolic function (18% vs. 7%,  $p < 0.001$ ), and less often had heart failure with systolic dysfunction (17% vs. 26%,  $p < 0.001$ ). Among patients with typical atrial fibrillation symptoms (56% of women, 49% of men), there was no gender-related difference in the choice of rate or rhythm control. Among patients with atypical or no symptoms (44% of women, 51% of men), women less frequently underwent rhythm control (39% vs. 51%,  $p < 0.001$ ) than did men. Women underwent less electrical cardioversion (22% vs. 28%,  $p < 0.001$ ). Prescription of oral anticoagulants was identical (65%) in both genders, although women showed a higher prevalence of additional risk factors for stroke, as indicated by higher CHADS2 scores. One-year outcome was similar, except that women had a higher chance for stroke, independent of age and additional risk factors (odds ratio 1.83 in multivariable regression analysis,  $p = 0.019$ ). Thus, women with atrial fibrillation in the European countries had more comorbidities, a lower QoL, and a higher risk for stroke than men.

Women have a greater risk of developing adverse drug reactions than men. In fact, female prevalence is higher than expected among patients with torsades des pointes induced by drugs which prolong ventricular repolarization and a review

\* Available on-line on

<http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>



of reported cases of cardiovascular drug-related torsades des pointes showed a female prevalence of 70% (190). Among patients who received d-l sotalol, a drug used for both restoring and maintaining sinus rhythm in atrial fibrillation, torsades des pointes developed in 1.9% of males and in 4.1% of females (191). Furthermore, in the Sportif V trial women were more prone to anticoagulant-related bleeding and to higher rate of thrombo-embolism due to more frequent interruption of anticoagulant therapy (192).

The 2006 European Society of Cardiology Guidelines for the management of patients with atrial fibrillation (172) addresses the gender issues. They define female gender as an additional risk factor for stroke, especially in patients over the age of 75 and recommend antithrombotic therapy with either aspirin or a vitamin K antagonist for prevention of thromboembolism. They also include female gender as a risk factor for frequent recurrence of paroxysmal atrial fibrillation and for drug-induced ventricular arrhythmias.

## Gender differences in stroke

Stroke is a major cause of death in both men and women and represents the first cause of disability and the second cause of dementia (1,2). Several risk factors for ischemic heart disease increase also the predisposition for stroke. Accordingly, the identification of patients at risk and the correction of risk factors is the basis of prevention of both ischemic heart disease and stroke. However, approximately 20% of stroke is not explained by the presence of traditional risk factors and it has been hypothesized that genetic factors may play a role. It has recently been shown that heritability of ischemic stroke is greater in women than in men, with an excess of affected mothers and affected sisters in female probands, independent of traditional vascular risk factors (193).

Clinical trials on the treatment of stroke enrolled a fair proportion of women (194-207) (See appendix 9\*). Overall 10 randomized clinical trials enrolled 28,790 patients and 10,618 were women (36.9%).

Mean age of participants was 69 years and mean follow-up was 1.26 years, as the majority of trials have been performed in the acute phase of stroke. The percentage of women enrolled in each trial ranges from 25% to 52% and 5/10 trials (50%) reported the analysis of the results by gender.

Gender differences in the clinical presentation and outcome of stroke have been demonstrated. In the Framingham Study (208) 5,119 individuals (2,829 women) and 4,957 offspring (2,565 women) were followed to first incident stroke. Among the 1,136 incident strokes (638 in women) over 5.6 years of follow-up women were significantly older (75.1 vs 71.1 years for men;  $P < 0.001$ ) at their first-ever stroke, had a higher stroke incidence above the age of 85, and a higher lifetime risk of stroke at all ages. There was no significant difference in stroke subtype, stroke severity, and case fatality rates between genders. Women were significantly ( $P < 0.01$ ) more disabled in the acute phase, at 3 to 6 months after stroke and 3.5 times more likely to be institutionalized ( $P < 0.01$ ). These results support the existence of gender-differences in stroke incidence, lifetime risk of stroke, age at first stroke, post stroke disability, and institutionalization rates.

**It has been shown that gender differences in clinical management after an acute stroke also exist.**

It has been shown that gender differences in clinical management after an acute stroke also exist (2,209,210). A multicenter study conducted in 7 European countries (210) showed that after an acute cerebrovascular event, brain imaging, Doppler examination, echocardiogram, and angiography were significantly less often performed in female than in male patients. Furthermore, there is evidence that women, especially of older age, are less likely to receive lipid lowering drugs and antithrombotics for secondary prevention of stroke (211).

Thrombolytic therapy is the only approved intervention for acute ischemic stroke. A meta-analysis showed that women benefit more than

\* Available on-line on

<http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>

men from this therapy (212). The beneficial effect of thrombolytic therapy is particularly evident when administered early after the onset of symptoms but two recent studies demonstrated that this therapy is effective also after 3 hours from the onset of symptoms, if administered within 4.5 hours (201,213). However, the metabolic syndrome, which is more prevalent in women, confers a higher resistance to intravenous thrombolysis in acute middle cerebral artery ischemic stroke and this effect appears to be more pronounced in women than in men (214).

Intra-arterial thrombolysis is equally effective to intravenous thrombolysis, but the therapeutic window is extended to 6 hours from the onset of symptoms. In the PROACT-2 study of intra-arterial stroke thrombolysis (196), women showed a larger treatment effect (20% absolute benefit) compared with men (10% absolute benefit). The reason for this interaction is probably that thrombolytic treatment nullifies the worse outcome for untreated women compared with men.

**Despite the greater efficacy in women of thrombolytic therapy, the percentage of women who do not receive rt-PA after acute ischemic stroke is higher compared to men.**

However, despite the greater efficacy of thrombolytic therapy, the percentage of women who do not receive rt-PA after acute ischemic stroke is higher compared to men. A meta-analysis to determine whether a sex disparity existed, showed that

women had a 30% lower probability of receiving rt-PA treatment than men (215). Further studies to explore the origins of this sex disparity are warranted. Thrombolytic therapy after stroke should be administered within the first 3-4.5 hours after the onset of symptoms, since after this period the risk of bleedings outweighs the benefit of treatment. The percentage of women who reach the hospital within this time period is lower than that of men and this observation may partially explain the under-treatment of women with thrombolytic therapy (210). Among 1,922 acute stroke cases who presented in 15 hospitals participating in a state-wide stroke registry (216), women were significantly less likely than men to present with any stroke warning sign or suspected stroke (87.5% versus 91.4%). In adjusted analyses, women had 11% longer door-to-doctor intervals and 15% longer door-to-image intervals. Furthermore, these gender differences remained evident after restricting to patients who arrived within 6 or within 2 hours of symptom onset. Thus, women with acute stroke experienced greater delays in an emergency department than men, which were not attributable to differences in presenting symptoms, time of arrival, age, or other confounders.

The 2008 Guidelines for management of ischemic stroke and transient ischemic attack of the European Stroke Organization (92) included gender issues in the text but they recommend the same management and treatment for women and men. The only gender-specific recommendation is on the use of aspirin for the primary prevention of stroke in women and not in men, as mentioned before.



## Conclusions

Cardiovascular diseases are the leading cause of mortality in women and in men (1). Coronary heart disease represents the majority of deaths in both genders, whereas stroke is a relatively more frequent cause of death in women than in men (2). Despite this unequivocal epidemiological observation, confirmed by the data released by the WHO in 2008, the cardiovascular risk in females is underestimated because women are perceived to be protected against cardiovascular diseases (217). However, the prevalence of cardiovascular diseases in women is lower than in men during the fertile age but it increases after menopause. The misperception of the actual risk in this period may leave most women without appropriate preventive measures (2). Furthermore, the clinical manifestations of ischemic heart disease in women may be different from those commonly observed in men, thus leading to a delay in the diagnosis (217).

Under-representation of women in clinical trials performed in the past has been clearly demonstrated. The European scientific societies and the foundations involved in the field of cardiovascular diseases have taken initiatives to increase the representation of women in cardiovascular research. European institutions, national research authorities and regulatory agencies have been involved in increasing efforts to enrol a larger number of women in clinical trials.

One of the objectives of the EuroHeart project (WP6) was to assess the representation of women in cardiovascular research in Europe in the last years. The search was conducted in order to identify publications (European or international with European representation) of observational/epidemiological studies, randomized clinical trials, meta-analyses, which enrolled women and men or women only, European registries, Guidelines and Statements of European Scientific Societies. Studies that did not involve European subjects were not considered. The number and percentage of women enrolled in the studies, age of participants, time of follow-up, availability of the analysis of outcomes by gender, identification of gender differences in risk, outcome or clinical practice, and inclusion of

gender issues in the European scientific guidelines have been considered.

The analysis has been performed specifically on studies focused on the evaluation of cardiovascular risk, management of menopause and hormone replacement therapy, blood pressure and lipid lowering interventions, diabetes, antithrombotic therapies, clinical management and treatment of ischemic heart disease, heart failure, atrial fibrillation and stroke.

Overall, the 62 randomized clinical trials published since 2006 and analyzed here (table 1), enrolled 380,891 participants and 127,716 were women (33.5%) (Figure 1 and 2). Mean age of participants was 66.3 years (figure 3) and mean follow-up 2.7 years (figure 4). The percentage of women enrolled in each trial ranges from 15% to 60%, but only 31/62 trials (50%) reported the analysis of the results by gender (figure 5).

However, the representation of women in the clinical trials is not homogeneous. Trials performed on blood pressure-lowering therapies, diabetes, atrial fibrillation and stroke enrolled a higher proportion of women (approximately 40%) but the results by gender were reported only in about half of the trials. Trials performed on cholesterol-lowering therapy and on management and treatment of ischemic heart disease and heart failure have enrolled the lowest proportion of women (about 30%). The number of trials which reported the results according to gender varied from 82% in the heart failure trials to the extremely low figure of 18% (1 of 6) for trials on cholesterol-lowering therapy.

Despite an increase in the number and proportion of women enrolled in cardiovascular clinical trials, there is still an under-representation of women, particularly in the field of cholesterol-lowering therapy, ischemic heart disease and heart failure, which may have affected the reliability of subgroup analysis. Furthermore, approximately 50% of the trials did not report an analysis of the results by gender, and this occurred also for studies which enrolled a large number of men and women. The duration

of follow-up may have influenced the number of events in women when compared with those occurring in men, as females of the same age as males may be at lower risk at the time of enrolment. This difference should be taken into account in the design of a clinical trial. One of the reasons of a lower enrolment of women in clinical trials is indeed the lower occurrence of outcomes in females, which may affect the costs of the study. This apparent conflict between adequate enrolment of women and cost-effective trial execution may be overcome by a more accurate choice of the inclusion criteria. A positive example comes from the recent JUPITER trial of primary prevention with statins, where men over the age of 50 and women over the age of 60 have been enrolled.

The reason of the under-representation of females in cardiovascular research may also be partly explained by a lower willingness of women to be enrolled, due to their misperception of risk of cardiovascular diseases. Another explanation might be the difficulties in terms of transportation or support for the follow-up visits. Barriers to the enrolment of women in clinical trials should therefore be removed in order to increase the proportion of women studied.

Most of the clinical trials and meta-analyses on cardiovascular diseases analyzed here, did not report a significantly lower efficacy of interventions in women compared with men. For some therapies there is even a suggestion of greater efficacy in women than in men, as in the case of cardiac resynchronization therapy in heart failure or thrombolysis after ischemic stroke. Accordingly, Scientific Guidelines do not generally provide specific recommendations for prevention or treatment in women.

The studies which reported some gender differences are those on primary prevention with aspirin in individuals without signs of cardiovascular disease. Although the benefit of this therapy is modest in both asymptomatic men and women, it appears that aspirin reduces the risk of coronary heart disease in men and of stroke in women. However, other factors,

such as the overall risk of cardiovascular mortality, the risk of bleedings and age, rather than gender, should influence the choice of this antithrombotic therapy.

Another finding is the greater occurrence of adverse effects of drugs and procedures in women than in men. This effect has been observed in diabetic women treated with thiazolidinediones who experienced an excess of bone fractures, as opposed to their male counterpart, or in the treatment of acute coronary syndromes where women appear to be more prone to bleedings.

Finally, in some areas, clinical trials provided somewhat conflicting results in women, as in the assessment of the efficacy of early invasive strategies in acute coronary syndromes. In this case only the design of large-scale randomized trials in women may contribute to determine the most appropriate strategy for management and treatment.

The Statement of the Policy Conference on Cardiovascular Diseases in Women in 2006 (2) provided priorities and recommendations for the improvement of risk stratification, diagnosis and treatment of cardiovascular diseases in women. Although some improvement in this field has occurred, it is still extremely urgent to collect epidemiological data for cardiovascular diseases and risk factors in women of different age groups in Europe in order to improve the accuracy of risk charts to predict the risk of cardiac events in females (2). Moreover, it is necessary to tailor the risk assessment process to incorporate risk factors that are particularly important for women, i.e. diabetes, obesity and smoking and extend risk assessment to older age groups in order to account for the delayed onset of cardiovascular diseases in women (2). The assessment of the predictive value of diagnostic procedures by gender should be encouraged and the implementation of the recommendations of clinical guidelines with respect to the adoption of preventive measures and optimal medical therapy in women should be promoted (2). The recommendation on cardiovascular research in women of the Policy Conference released in 2006



(2) should be followed and implemented. Although non prespecified, post-hoc, subgroup analysis by gender for already completed clinical trials with adequate power and representation of women may help to explore the issue of gender differences, clinical trials enrolling only female patients or clinical trials enrolling a significant proportion of women to allow for prespecified gender analysis should be conducted (2).

Educational activities to increase awareness about morbidity and mortality related to cardiovascular diseases in women should be implemented and targeted to different audiences including health care professionals, the medical community, the stakeholders in this field and also the general population.

Initiatives which contribute to increase the awareness in Europe that cardiovascular diseases are the major cause of death in women and to improve the knowledge of risk factors, presentation and treatment of cardiovascular diseases in women should be encouraged. Scientific societies, patients' associations and foundations should cooperate with European institutions, national health care authorities and regulatory agencies to promote scientific research on sex and gender issues in cardiovascular medicine. Furthermore, a larger representation of women in clinical trials should increase the understanding of gender differences in the response to drug therapy and specific gender-related recommendations for prevention, management and treatment of cardiovascular diseases could be provided in the future where possible.

# Table and Figures


## Table 1 - Clinical trials

This table contains a summary of the 62 randomised clinical trials published since 2006 and analysed in this report. More detailed information on each of the topics can be found in the appendices which form an integral part of this report. These appendices can be consulted on-line on

<http://www.ehnheart.org/content/ItemPublication.asp?docid=7441&level0=1456&level1=2096&level2=2100>


TOPICS	NUMBER OF PARTICIPANTS	NUMBER OF WOMEN	PERCENTAGE OF WOMEN	MEAN AGE	MEAN FOLLOW-UP (YEARS)	TRIALS WITH ANALYSIS BY GENDER N, (%)
BLOOD PRESSURE- LOWERING TREATMENT	69,473	28,008	40.3%	70.2	3.2	3/5 (60%)
DIABETES AND METABOLIC SYNDROME	48,508	20,091	41.4%	61.1	4.3	4/7 (57.1%)
CHOLESTEROL- LOWERING THERAPY	50,194	15,036	30.0%	60.8	3.2	1/6 (16.7%)
ANTITHROMBOTIC THERAPY AND OTHER INTERVENTIONS	24,874	7,181	28.9%	65.3	3.4	2/3 (66.7%)
ISCHAEMIC HEART DISEASE	90,400	24,756	27.3%	62.6	0.96	5/13 (38.4%)
HEART FAILURE	46,141	12,834	27.8%	69.2	2.4	8/11 (72.7%)
ATRIAL FIBRILLATION	22,511	9,192	40.8%	72.1	2.5	3/7 (42.8%)
STROKE	28,790	10,618	36.9%	69.0	1.26	5/10 (50%)
<b>TOTAL</b>	<b>380,891</b>	<b>127,716</b>	<b>33.5%</b>	<b>66.3</b>	<b>2.7</b>	<b>31/62 (50.0%)</b>

**Figure 1 - Participants in clinical trials by gender**




BP: blood pressure; DM: diabetes mellitus; Chol: cholesterol; Asp: aspirin; IHD: ischemic heart disease; HF: heart failure; Afib: atrial fibrillation.

**Figure 2 - Percentage of women in clinical trials**




BP: blood pressure; DM: diabetes mellitus; Chol: cholesterol; Asp: aspirin; IHD: ischemic heart disease; HF: heart failure; Afib: atrial fibrillation.

**Figure 3 - Mean age of participants in clinical trials**




BP: blood pressure; DM: diabetes mellitus; Chol: cholesterol; Asp: aspirin; IHD: ischemic heart disease; HF: heart failure; Afib: atrial fibrillation.

**Figure 4 - Mean follow-up of clinical trials**



BP: blood pressure; DM: diabetes mellitus; Chol: cholesterol; Asp: aspirin; IHD: ischemic heart disease; HF: heart failure; Afib: atrial fibrillation.

**Figure 5 - Clinical trials with analysis by gender**



BP: blood pressure; DM: diabetes mellitus; Chol: cholesterol; Asp: aspirin; IHD: ischemic heart disease; HF: heart failure; Afib: atrial fibrillation.

# References

1. World Health Organization Statistical Information System 2008. [www.who.int/whosis/](http://www.who.int/whosis/)
2. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, Jonsson B, Schenck-Gustafsson K, Tendera M. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. *Eur Heart J* 2006 ; 27(8):994-1005.
3. Stramba-Badiale M, Priori SG. Gender-specific prescription for cardiovascular diseases? *Eur Heart J* 2005;26:1571-2.
4. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JAE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005;352:1293-304.
5. Jagger C, Gillies C, Moscone F, Cambois E, Van Oyen H, Nusselder W, Robine JM; EHLEIS team. Inequalities in healthy life years in the 25 countries of the European Union in 2005: a cross-national meta-regression analysis. *Lancet* 2008;372(9656):2124-31.
6. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. *N Engl J Med* 2000;343:475-480.
7. Kim C, Fahrenbruch CE, Menon V. Enrollment of women in National Heart, Lung, and Blood Institute-Funded cardiovascular controlled trials fails to meet current federal mandates for inclusion. *JACC* 2008;52: 672-673.
8. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. *N Engl J Med* 1987 30;316:1105-10.
9. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Östergren J, Toumilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2007;28(1):88-136.
10. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE. Abdominal adiposity and coronary heart disease in women. *JAMA* 1998;280(21):1843-8.
11. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *JAMA* 2003;289(1):76-9.
12. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. *Am Heart J* 1987;114(2):413-9.
13. Leonetti G, Cuspidi C, Facchini M, Stramba-Badiale M: Is systolic pressure a better target for antihypertensive treatment than diastolic pressure? *J Hypertens* 2000; 18 (Suppl 3):S13-S20.
14. Staessen JA, Celis H, Fagard R. The epidemiology of the association between hypertension and menopause. *J Hum Hypertens*. 1998 Sep;12(9):587-92.
15. Stramba-Badiale M. Postmenopausal hormone therapy and the risk of cardiovascular disease. *J Cardiovasc Med (Hagerstown)* 2009;10(4):303-9.
16. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. *Prev Med* 1991; 20:47-63.
17. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. *Ann Intern Med* 1992; 117:1016-1037.
18. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. *Eur Heart J* 2008;29(16):2031-41.
19. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. *BJOG* 2006; 113:5-14.
20. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. *Circulation* 2004;109(5):672-93.
21. Mosca L, Banka CL, Benjamin EJ, Berra K, Haan CK, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK; Expert Panel/Writing Group; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. 2007 update. *Circulation* 2007;115:1481-1501.
22. Naftolin F, Schneider HP, Sturdee DW, Birkhauser M, Brincat MP, Gambacciani M, Genazzani AR, Limpaphayom KK, O'Neill S, Palacios S, Pines A, Siseles N, Tan D, Burger HG; Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. *Climacteric* 2004;7: 333-337.



23. Collins P. Risk factors for cardiovascular disease and hormone therapy in women. *Heart* 2006;92:24-28.
24. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sándwich L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. *Maturitas* 2005;52:111-118.
25. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration and progestogens: The ESTHER study. *Circulation* 2007;115:840-845.
26. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA*. 2007 Apr 4;297(13):1465-77. Erratum in: *JAMA*. 2008 Mar 26;299(12):1426.
27. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. *Am J Epidemiol* 2009;170(1):12-23.
28. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walzer M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. *JAMA*. 2006 May 3;295(17):2057-71.
29. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. *N Engl J Med* 2006;355(2):125-37.
30. Collins P, Mosca L, Geiger MJ, Grady D, Kornitzer M, Amewou-Atisso MG, Efron MB, Dowsett SA, Barrett-Connor E, Wenger NK. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. *Circulation*. 2009 Feb 24;119(7):922-30.
31. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; the LIFT Trial Investigators. The Effects of Tibolone in Older Postmenopausal Women. *N Engl J Med*. 2008;359(7):697-708.
32. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, Kaaja R, Mikkola T, Palacios S, Preston R, Simon T, Stevenson J, Stramba-Badiale M. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. *Eur Heart J* 2007;28(16):2028-40. Epub 2007 Jul 20.
33. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyörälä K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellems I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancina G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoğlu L, Wiklund O, Zampelas A; European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); Society of Behavioural Medicine (ISBM); European Society of Hypertension (ESH); WONCA Europe (European Society of General Practice/Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur J Cardiovasc Prev Rehabil*. 2007 Sep;14 Suppl 2:S1-113.
34. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;24(11):987-1003.
35. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. 2007 Feb 14;297(6):611-9. Erratum in: *JAMA*. 2007;297(13):1433.
36. Korngold EC, Januzzi JL Jr, Gantzer ML, Moorthy MV, Cook NR, Albert CM. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. *Circulation*. 2009;119(22):2868-76.
37. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med*. 2006 Apr 13;354(15):1578-88.

38. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med*. 2006 Apr 13;354(15):1567-77. Erratum in: *N Engl J Med*. 2006 Aug 17;355(7):746.
39. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. *Lancet*. 2009;373(9667):929-40.
40. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Hunter DJ, Hennekens CH, Speizer FE. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. *Ann Intern Med* 1993; 119:992-1000.
41. Asia Pacific Cohort Studies Collaboration. Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. *Int J Epidemiol* 2005; 34:1036-1045.
42. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. *Circulation* 1996; 93:450-456.
43. Benowitz N, Lessov-Schaggar CN, Swan G, Jacob P 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. *Clin Pharmacol Ther* 2006; 79:480-488.
44. Keeling D. Combined oral contraceptives and the risk of myocardial infarction. *Ann Med* 2003; 35:413-418.
45. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. *Arch Intern Med* 2000; 160:939-944.
46. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward W, MacMahon S, on behalf of the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ* 2008;336: 1121-1123.
47. Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, Reboldi G. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. *Eur Heart J*. 2009 Mar;30(6):679-88.
48. Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. *Eur Heart J*. 2009 Jun;30(11):1385-94.
49. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008 May 1;358(18):1887-98.
50. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr 10;358(15):1547-59.
51. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaitiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet*. 2008 Aug 16;372(9638):547-53.
52. Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. *Lancet*. 2008 Sep 27;372(9644):1174-83. Epub 2008 Aug 29. Erratum in: *Lancet*. 2008 Oct 18;372(9647):1384.
53. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*. 2008 Dec 4;359(23):2417-28.
54. Bangalore S, Messerli FH, Franklin SS, Mancina G, Champion A, Pepine CJ. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an International Verapamil SR-trandolapril Study (INVEST) analysis. *Eur Heart J*. 2009 Jun;30(11):1395-401.
55. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, Perkovic V, Li N, MacMahon S; Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. *Eur Heart J*. 2008 Nov;29(21):2669-80.
56. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekblom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. *Ann Intern Med*.



- 1997;126(10):761-7.
57. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellmans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waerber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens.* 2007;25(6):1105-87. Erratum in: *J Hypertens.* 2007;25(8):1749.
  58. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A, Mengden T, O'Brien E, Ohkubo T, Padfield P, Palatini P, Pickering T, Redon J, Revera M, Ruilope LM, Shennan A, Staessen JA, Tisler A, Waerber B, Zanchetti A, Mancia G; ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. *J Hypertens* 2008;26(8):1505-26.
  59. Paradisi G, Biaggi A, Savone R, Ianniello F, Tomei C, Caforio L, Caruso A. Cardiovascular risk factors in healthy women with previous gestational hypertension. *J Clin Endocrinol Metab* 2006; 91:1233–1238.
  60. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. *Br Med J* 2003; 326:845–851.
  61. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Scherthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet.* 2005 Oct 8;366(9493):1279-89.
  62. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet.* 2005 Nov 26;366(9500):1849-61. Erratum in: *Lancet.* 2006 Oct 21;368(9545):1415. *Lancet.* 2006 Oct 21;368(9545):1420.
  63. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. *Lancet.* 2009 May 23;373(9677):1780-8.
  64. DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanus F, Probstfield J, Fodor G, Holman RR. Effect of ramipril on the incidence of diabetes. *N Engl J Med.* 2006 Oct 12;355(15):1551-62.
  65. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008 Jun 12;358(24):2560-72.
  66. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008 Jun 12;358(24):2545-59.
  67. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med.* 2009 Jun 11;360(24):2503-15.
  68. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet.* 2009 Jun 20;373(9681):2125-35.
  69. Casey BM, Lucas MJ, McIntire DD, Leveno KJ. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. *Obstet Gynecol* 1997; 90: 869–73.
  70. Kozhimannil KB, Pereira MA, Harlow BL. Association between diabetes and perinatal depression among low-income mothers. *JAMA.* 2009 Feb 25;301(8):842-7.
  71. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review.

- Diabetes Care 2002; 25: 1862–68.
72. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet*. 2009 May 23;373(9677):1773-9.
  73. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009 May 23;373(9677):1765-72.
  74. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. *CMAJ*. 2009 Jan 6;180(1):32-9.
  75. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2009 Jan;32(1):193-203.
  76. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009 May 23;373(9677):1765-72.
  77. Amarenco P, Bogouslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Silleesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med*. 2006 Aug 10;355(6):549-59
  78. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascularevents in patients with stable coronary disease in the TNT (treating to newtargets) study. *J Am Coll Cardiol*. 2006 Nov 7 ;48(9):1793-9.
  79. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*. 2007 Nov 22;357(21):2109-22.
  80. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med*. 2008 Apr 3;358(14):1431-43. Epub 2008 Mar 30. Erratum in: *N Engl J Med*. 2008 May 1;358(18):1977.
  81. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerds E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med*. 2008 Sep 25;359(13):1343-56.
  82. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascularevents in men and women with elevated C-reactive protein. *N Engl J Med*. 2008 Nov 20;359(21):2195-207.
  83. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. *N Engl J Med*. 2009 Apr 30;360(18):1851-61.
  84. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. 2005 Oct 8;366(9493):1267-78. Epub 2005 Sep 27. Erratum in: *Lancet*. 2005 Oct 15-21;366(9494):1358. *Lancet*. 2008 Jun 21;371(9630):2084.
  85. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. *Clin Ther*. 2009 Feb;31(2):236-44.
  86. Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: A meta-analysis. *Int J Cardiol*. 2008 Sep 13.
  87. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ*. 2009 Jun 30;338:b2376.
  88. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009 May 30;373(9678):1849-60.
  89. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. *JAMA*. 2009 May 13;301(18):1909-19.



90. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. *JAMA*. 2006 Jan 18;295(3):306-13.
91. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009 Mar 17;150(6):396-404.
92. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack. 2008 [www.eso-stroke.org](http://www.eso-stroke.org).
93. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. *Lancet*. 2006 Feb 18;367(9510):569-78.
94. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. *J Am Coll Cardiol*. 2006 Jul 4;48(1):37-42. Epub 2006 Jun 12.
95. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. *Circulation*. 2007 Dec 18;116(25):2923-32. Epub 2007 Dec 3.
96. Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, van Domburg R, Serruys PW; Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Long-Term Outcome After Bare Metal and Drug-Eluting Stent Implantation *Circ Cardiovasc Intervent* 2008;1:103-110.
97. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007 Nov 15;357(20):2001-15.
98. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. *Eur Heart J*. 2008 Oct;29(20):2473-9.
99. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. *Lancet*. 2009 Feb 28;373(9665):723-31.
100. Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. *Eur Heart J*. 2009 Apr;30(8):900-7.
101. Tizón-Marcos H, Bertrand OF, Rodés-Cabau J, Larose E, Gaudreault V, Bagur R, Gleeton O, Courtis J, Roy L, Poirier P, Costerousse O, De Larochelière R. Impact of female gender and transradial coronary stenting with maximal antiplatelet therapy on bleeding and ischemic outcomes. *Am Heart J*. 2009 Apr;157(4):740-5.
102. Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, Gersh BJ, Ohman EM, White HD, Moses JW, Ware JH, Lincoff AM, Stone GW. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. *J Am Coll Cardiol*. 2009 May 26;53(21):1965-72.
103. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzensichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. *N Engl J Med*. 2009 May 7;360(19):1946-59.
104. James SK, Stenestrand U, Lindbäck J, Carlsson J, Scherstén F, Nilsson T, Wallentin L, Lagerqvist B; SCAAR Study Group. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. *N Engl J Med*. 2009 May 7;360(19):1933-45.
105. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators. Early versus delayed, provisional eptifibatid in acute coronary syndromes. *N Engl J Med*. 2009 May 21;360(21):2176-90.
106. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stähle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med*. 2009 Mar 5;360(10):961-72.
107. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum

- A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. *N Engl J Med*. 2009 May 21;360(21):2165-75.
108. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. *N Engl J Med*. 2007 Mar 8;356(10):998-1008.
  109. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. *Lancet*. 2008 Dec 6;372(9654):1962-76. Erratum in: *Lancet*. 2009 May 23;373(9677):1764.
  110. Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, Dangas G. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2009 May 5;53(18):1677-89.
  111. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. *N Engl J Med* 1996;334:1311-5.
  112. Hochman JS, McCabe CH, Stone PH, Becker RC, Cannon CP, DeFeo-Fraulini T, Thompson B, Steingart R, Knatterud G, Braunwald E. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. *J Am Coll Cardiol* 1997;30:141-8.
  113. Stramba-Badiale M, Bonazzi O, Casadei G, Dal Palu C, Magnani B, Zanchetti A. J Hypertens. Prevalence of episodes of ST-segment depression among mild-to-moderate hypertensive patients in northern Italy: the Cardioscreening Study. *J Hypertens* 1998;16:681-8.
  114. Kannel WB, Dannenberg AL, Abbott RD. Unrecognized myocardial infarction and hypertension: the Framingham Study. *Am Heart J* 1985;109:581-5.
  115. Hemingway H, Langenberg C, Damant J, Frost C, Pyörälä K, Barrett-Connor E. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. *Circulation*. 2008 Mar 25;117(12):1526-36.
  116. Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F, Aylward P, Topol EJ, Califf RM. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. *N Engl J Med* 1999;341:226-32.
  117. Sullivan AK, Holdright DR, Wright CA, Sparrow JL, Cunningham D, Fox KM. Chest pain in women: clinical, investigative, and prognostic features. *BMJ* 1994;308:883-6.
  118. Miller TD, Roger VL, Milavetz JJ, Hopfenspirger MR, Milavetz DL, Hodge DO, Gibbons RJ. Assessment of the exercise electrocardiogram in women versus men using tomographic myocardial perfusion imaging as the reference standard. *Am J Cardiol* 2001;87:868-73.
  119. Mieres JH, Shaw LJ, Arai A, Budoff MJ, Flamm SD, Hundley WG, Marwick TH, Mosca L, Patel AR, Quinones MA, Redberg RF, Taubert KA, Taylor AJ, Thomas GS, Wenger NK; Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: Consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. *Circulation* 2005;111(5):682-96.
  120. Stangl V, Witzel V, Baumann G, Stangl K. Current diagnostic concepts to detect coronary artery disease in women. *Eur Heart J*. 2008 Mar;29(6):707-17.
  121. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, Zineh I, Kelsey SF, Arnsdorf MF, Black HR, Pepine CJ, Merz CN. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St. James Women Take Heart Project. *Arch Intern Med*. 2009;169(9):843-850
  122. Daly CA, Clemens F, Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM; Euro Heart Survey Investigators. The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina. *Eur Heart J* 2005;26(10):996-1010.
  123. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjelm Dahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. *Eur Heart J*. 2006 Jun;27(11):1341-81.
  124. Elsaesser A, Hamm CW. Acute coronary syndrome: the risk of being female. *Circulation* 2004;109(5):565-7.
  125. Hasdai D, Porter A, Rosengren A, Behar S, Boyko V, Battler A. Effect of gender on outcomes of acute coronary



syndromes. *Am J Cardiol* 2003; 91:1466–1469.

126. MacIntyre K, Stewart S, Capewell S, Chalmers JW, Pell JP, Boyd J, Finlayson A, Redpath A, Gilmour H, McMurray JJ. Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction. *J Am Coll Cardiol* 2001;38:729–735.
127. Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F, Aylward P, Topol EJ, Califf RM. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. *N Engl J Med* 1999;341:226–232.
128. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX Jr, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LK. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol* 2005;45:832–837.
129. Swahn E, Alfredsson J, Afzal R, Budaj A, Chrolavicius S, Fox K, Jolly S, Mehta SR, de Winter R, Yusuf S. Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. *Eur Heart J*. 2009 Feb 7. [Epub ahead of print].
130. O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. *JAMA*. 2008 Jul 2;300(1):71–80.
131. Jacobs AK, Kelsey SF, Brooks MM, Faxon DP, Chaitman BR, Bittner V, Mock MB, Weiner BH, Dean L, Winston C, Drew L, Sopko G. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). *Circulation* 1998;98(13):1279–85.
132. Dodge JT Jr, Brown BG, Bolson EL, Dodge HT. Lumen diameter of normal human coronary arteries. Influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation. *Circulation* 1992;86(1):232–46.
133. Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. *J Am Coll Cardiol* 1999; 34(1):40–8.
134. Jacobs AK, Johnston JM, Haviland A, Brooks MM, Kelsey SF, Holmes DR, et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the national Heart, Lung, and Blood Institute Dynamic Registry. *J Am Coll Cardiol* 2002;39: 1608–14.
135. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. *J Am Coll Cardiol* 2000;36(2):381–6.
136. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HR, Strickland W, Mehran R, Leon MB, Russell ME, Ellis SG, Stone GW; TAXUS-IV Investigators. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. *J Am Coll Cardiol* 2005;45: 1180–5.
137. Solinas E, Nikolsky E, Lansky AJ, Kirtane AJ, Morice MC, Popma JJ, Schofer J, Schampaert E, Pucelikova T, Aoki J, Fahy M, Dangas GD, Moses JW, Cutlip DE, Leon MB, Mehran R. Gender-specific outcomes after sirolimus-eluting stent implantation. *J Am Coll Cardiol*. 2007 Nov 27;50(22):2111–6.
138. Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, Sechtem U, Stahle E, Widimsky P, de Jaegere P, Scholte op Reimer WJ, Mercado N, Wijns W. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. *Eur Heart J* 2005;26:1169–1179.
139. Solodky A, Behar S, Boyko V, Battler A, Hasdai D. The outcome of coronary artery bypass grafting surgery among patients hospitalized with acute coronary syndrome: the Euro Heart Survey of acute coronary syndrome experience. *Cardiology* 2005;103:44–47.
140. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA*. 2002 Nov 20;288(19):2411–20. Erratum in: *JAMA*. 2003 Feb 26;289(8):987.
141. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaud L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006 Apr 20;354(16):1706–17.
142. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, Roe MT, Gibler WB, Ohman EM, Peterson

- ED; CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Investigators. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. *Circulation*. 2006 Sep 26;114(13):1380-7.
143. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J*. 2007 Jul;28(13):1598-660.
  144. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellems I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di Mario C, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J*. 2008 Dec;29(23):2909-45.
  145. Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJ. Failure of women's hearts. *Circulation* 1999;99(17):2334-41.
  146. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol* 1993;22(4 Suppl A):6A-13A.
  147. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure PEP-CHF study. *Eur Heart J*. 2006 Oct;27(19):2338-45.
  148. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *JAMA*. 2007 Mar 28;297(12):1319-31.
  149. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. *JAMA*. 2007 Mar 28;297(12):1332-43.
  150. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, Ostergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. Sex differences in clinical characteristics and prognosis in broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. *Circulation*. 2007 Jun 19;115(24):3111-20.
  151. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, János A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med*. 2007 Nov 29;357(22):2248-61.
  152. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008 Oct 4;372(9645):1231-9.
  153. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008 Oct 4;372(9645):1223-30.
  154. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008 Sep 6;372(9641):807-16.
  155. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med*. 2008 Dec 4;359(23):2456-67.
  156. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hiltl P, Schindler R, Brunner-La Rocca HP; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. *JAMA*. 2009 Jan 28;301(4):383-92.
  157. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman



- KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. *Circulation*. 2009 Mar 31;119(12):1616-24. Epub 2009 Mar 16. PubMed PMID: 19289640.
158. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Piña IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*. 2009 Apr 8;301(14):1439-50.
159. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O'Connor CM, Weinfurt KP. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*. 2009 Apr 8;301(14):1451-9.
160. van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). *J Am Coll Cardiol*. 2009 Jun 9;53(23):2150-8.
161. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. *Eur Heart J*. 2006 Nov;27(22):2682-8.
162. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. *N Engl J Med* 2002;347:1403.
163. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. *JAMA* 2003;289:871.
164. Kimmelstiel C, Goldberg RJ. Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes. *Cardiology*. 1990;77 Suppl 2:71-9:71-9.
165. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L, et al. Efficacy of angiotensin converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. *J Am Coll Cardiol*. 2003;41:1529-38.
166. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW 3rd, Young JB, Probstfield J, for the SOLVD Investigators. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). *Am Heart J*. 1996;131:350-5.
167. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; the MADIT-CRT Trial Investigators. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. *N Engl J Med*. 2009 ;361:1329-38.
168. Frazier CG, Alexander KP, Newby LK, Anderson S, Iverson E, Packer M, Cohn J, Goldstein S, Douglas PS. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. *J Am Coll Cardiol*. 2007 Apr 3;49(13):1450-8.
169. Lenzen MJ, Rosengren A, Scholte op Reimer WJ, Follath F, Boersma E, Simoons ML, Cleland JG, Komajda M. Management of patients with heart failure in clinical practice: differences between men and women. *Heart*. 2008 Mar;94(3):e10.
170. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, Yancy CW, Albert NM, Peterson ED. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. *JAMA*. 2007 Oct 3;298(13):1525-32.
171. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Puri SG, Swedberg K; ESC Committee for Practice Guidelines, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellems I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J*. 2008 Oct;29(19):2388-442.
172. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise

- the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). *Eur Heart J* 2006;27:1979-2030.
173. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. *Circulation*. 2009 Apr 28;119(16):2146-52.
  174. Le Heuzey JY, Pazioud O, Piot O, Said MA, Copie X, Lavergne T, Guize L.. Cost of care distribution in atrial fibrillation patients: the COCAF study. *Am Heart J* 2004;147:121-6.
  175. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001;285:2370-5.
  176. Stramba-Badiale M. Atrial fibrillation subtypes, risk of stroke and antithrombotic therapy. *Eur Heart J* 2008;29:840-842.
  177. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischaemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. *Stroke* 1999;30: 1223-1229.
  178. Wang TJ, Massaro JM, Levy D, Vasas RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. *JAMA* 2003;290:1049-1056.
  179. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007 Jun 19;146(12):857-67.
  180. Pérez-Gómez F, Iriarte JA, Zumalde J, Berjón J, Salvador A, Alegría E, Maluenda MP, Asenjo S, Perez-Saldaña R, de la Torre RG, Bover R, Fernández C. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial. *Eur Heart J*. 2007 Apr;28(8):996-1003.
  181. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet*. 2006 Jun 10;367(9526):1903-12.
  182. Halonen J, Halonen P, Järvinen O, Taskinen P, Auvinen T, Tarkka M, Hippeläinen M, Juvonen T, Hartikainen J, Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. *JAMA*. 2007 Apr 11;297(14):1562-7.
  183. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet*. 2007 Aug 11;370(9586):493-503.
  184. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. *N Engl J Med*. 2009 Feb 12;360(7):668-78. Erratum in: *N Engl J Med*. 2009 Jun 4;360(23):2487.
  185. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med*. 2009 May 14;360(20):2066-78. Epub 2009 Mar 31.
  186. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G. Valsartan for prevention of recurrent atrial fibrillation. *N Engl J Med*. 2009 Apr 16;360(16):1606-17. Erratum in: *N Engl J Med*. 2009 May 28;360(22):2379.
  187. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. *Lancet*. 2006 Feb 4;367(9508):404-11.
  188. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. *Int J Cardiol*. 2008 May 23;126(2):160-70.
  189. Dagnes N, Nieuwlaat R, Vardas PE, Andresen D, Lévy S, Cobbe S, Kremastinos DT, Breithardt G, Cokkinos DV, Crijns HJGM: Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. A report from the Euro Heart Survey on Atrial Fibrillation. *J Am Coll Cardiol* 2007;49:572-7.
  190. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsade de pointe associated with cardiovascular drugs. *JAMA* 1993;270:2590-2597.
  191. Lehmann M.H., Hardy S, Archibald D, MacNeil DJ. JTC prolongation with d-l Sotalol in women versus men. *Am J Cardiol* 1999; 83: 354-359.
  192. Gombert-Maitland M, Wenger NK, Feyzi J, Lengyel M, Volgman AS, Petersen P, Frison L, Halperin JL. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. *Eur Heart J*. 2006 Aug;27(16):1947-53.
  193. Touzé E, Rothwell PM. Sex differences in heritability of ischemic stroke: a systematic review and meta-analysis. *Stroke*.



- 2008 Jan;39(1):16-23.
194. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet*. 2006 May 20;367(9523):1665-73. Erratum in: *Lancet*. 2007 Jan 27;369(9558):274.
  195. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. *Lancet Neurol*. 2007 Feb;6(2):115-24.
  196. Hill MD, Kent DM, Hinchey J, Rowley H, Buchan AM, Wechsler LR, Higashida RT, Fischbein NJ, Dillon WP, Gent M, Firszt CM, Schulz GA, Furlan AJ; PROACT-2 Investigators. Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. *Stroke*. 2006 Sep;37(9):2322-5.
  197. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. *Lancet Neurol*. 2008 Apr;7(4):299-309.
  198. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med*. 2008 Sep 18;359(12):1238-51.
  199. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. *N Engl J Med*. 2008 Sep 18;359(12):1225-37. Epub 2008 Aug 27.
  200. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. *Lancet Neurol*. 2008 Oct;7(10):875-84. Epub 2008 Aug 29. Erratum in: *Lancet Neurol*. 2008 Nov;7(11):985.
  201. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med*. 2008 Sep 25;359(13):1317-29.
  202. Mas JL, Trinquart L, Leys D, Albucher JF, Rousseau H, Viguier A, Bossavy JP, Denis B, Piquet P, Garnier P, Viader F, Touzé E, Julia P, Giroud M, Krause D, Hosseini H, Becquemin JP, Hinzelin G, Houdart E, Hénon H, Neau JP, Bracard S, Onnient Y, Padovani R, Chatellier G; EVA-3S investigators. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. *Lancet Neurol*. 2008 Oct;7(10):885-92.
  203. Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, Hennerici M, Stingele R, Fiehler J, Zeumer H, Jansen O. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. *Lancet Neurol*. 2008 Oct;7(10):893-902. Epub 2008 Sep 5. Erratum in: *Lancet Neurol*. 2009 Feb;8(2):135.
  204. Potter J, Mistri A, Brodie F, Chernova J, Wilson E, Jagger C, James M, Ford G, Robinson T. Controlling hypertension and hypotension immediately post stroke (CHHIPS)--a randomised controlled trial. *Health Technol Assess*. 2009 Jan;13(9):iii, ix-xi, 1-73.
  205. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebich JB, Gruber F, Kaste M, Lipka LJ, Pedraza S, Ringleb PA, Rowley HA, Schneider D, Schwamm LH, Leal JS, Söhngen M, Teal PA, Wilhelm-Ogunbiyi K, Wintermark M, Warach S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. *Lancet Neurol*. 2009 Feb;8(2):141-50.
  206. CLOTS Trials Collaboration, Dennis M, Sandercock PA, Reid J, Graham C, Murray G, Venables G, Rudd A, Bowler G. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. *Lancet*. 2009 Jun 6;373(9679):1958-65.

207. Gurm HS, Nallamothu BK, Yadav J. Safety of carotid artery stenting for symptomatic carotid artery disease: a meta-analysis. *Eur Heart J*. 2008 Jan;29(1):113-9.
208. Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA. Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. *Stroke* 2009 Apr;40(4):1032-7.
209. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CD, Giroud M, Rudd A, Ghetti A, Inzitari D; European BIOMED Study of Stroke Care Group. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. *Stroke* 2003;34(5):1114-9.
210. Goulene K, Santalucia P, Leonetti G, Stramba-Badiale M. Gender differences in the clinical presentation and outcome of acute stroke. *Stroke* 2006; 37: 648.
211. Raine R, Wong W, Ambler G, Hardoon S, Petersen I, Morris R, Bartley M, Blane D. Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study. *BMJ*. 2009 Apr 16;338:b1279.
212. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. *Stroke* 2005;36(1):62-5.
213. Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, Muir K, Roine RO, Toni D, Lees KR; SITS investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. *Lancet*. 2008 Oct 11;372(9646):1303-9.
214. Arenillas JF, Sandoval P, Pérez de la Ossa N, Millán M, Guerrero C, Escudero D, Dorado L, López-Cancio E, Castillo J, Dávalos A. The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men. *Stroke*. 2009 Feb;40(2):344-9.
215. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. *Stroke* 2001;32(8):1832-40.
216. Gargano JW, Wehner S, Reeves MJ. Do presenting symptoms explain sex differences in emergency department delays among patients with acute stroke? *Stroke*. 2009 Apr;40(4):1114-20.
217. Mosca L, Ferris A, Fabunmi R, Robertson RM; American Heart Association. Tracking women's awareness of heart disease: an American Heart Association national study. *Circulation* 2004;109:573-9.





*This report is produced as part of Work Package 6 of the EuroHeart project, which has received co-funding from the European Union in the framework of the Public Health programme (Grant A800239). The Executive Agency for Health and Consumers is not responsible for any use that may be made of the information provided in this report. The sole responsibility lies with the persons/organisations concerned.*

#### Contact details

**[www.ehnheart.org](http://www.ehnheart.org)**

European Heart Network  
Rue Montoyer 31  
B – 1000 Brussels  
Belgium  
Telephone: +32 2 512 91 74  
Fax : +32 2 503 35 25  
Email: [info@ehnheart.org](mailto:info@ehnheart.org)

**[www.escardio.org](http://www.escardio.org)**

European Society of Cardiology  
The European Heart House  
2035 Route des Colles - Les Templiers  
F - 06903 Sophia Antipolis  
France  
Telephone : +33.4.92.94.76.00  
Fax : +33.4.92.94.76.01

